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Abstract 
T-cell Acute Lymphoblastic Leukemia (T-ALL) is frequently characterized by glucocorticoid (GC) 
resistance, which is associated with inferior outcomes, thus highlighting the need for novel 
therapeutic approaches for GC resistant T-ALL. The pTCR/TCR signaling pathways play a critical role 
in cell fate decisions during physiological thymocyte development, with an interplay between TCR 
and glucocorticoid receptor (GR) signaling determining the T-lymphocyte selection process. We 
performed an shRNA screen in vitro and in vivo in T-ALL cell lines and patient derived xenograft 
(PDX) samples to identify vulnerabilities in the pTCR/TCR pathway and identified a critical role for 
the kinase LCK in cell proliferation. LCK knockdown or inhibition with dasatinib (DAS) caused cell 
cycle arrest. Combination of DAS with dexamethasone (DEX) resulted in significant drug synergy 
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leading to cell death. The efficacy of this drug combination was underscored in a randomized phase 
II-like murine trial, recapitulating an early phase human clinical trial. T-ALL expansion in 
immunocompromised mice was significantly impaired using this drug combination, relative to mice 
receiving control vehicle or single drug treatment, highlighting the immediate clinical relevance of 
this drug combination for high risk T-ALL patients. Our results thus provide a strategy to improve the 
efficacy of current chemotherapy platforms and circumvent GC resistance. 
Introduction 
Current minimal residual disease (MRD) stratified chemotherapy protocols for patients with T-ALL 
result in 5-year event free survival rates of 80% and 50% for pediatric and adult patients respectively 
(1, 2). Induction failure, early relapse and isolated central nervous system involvement are more 
common in T than B-lineage ALL (3). Moreover, resistance to conventional chemotherapy including 
GC is a frequent feature of relapsed and refractory T-ALL, reducing the second remission rate and 
long term outcomes (4). GC are an instrumental component of ALL therapy and induce apoptosis in 
lymphoid malignancies (5-7). Resistance to GC is a critical factor influencing treatment response and 
outcome (5, 8-11). Amongst ALL subtypes, GC resistance is more frequently observed in infant ALL 
and T-ALL (5, 9, 11, 12).  
Endogenous GC can induce apoptosis during the selection process of T-lymphocytes in the thymus, 
an effect which can be constrained by crosstalk with T cell receptor (TCR) signaling (13, 14). Whilst 
mature T-cell maintenance requires tonic TCR signaling, inappropriate TCR expression has been 
shown to give rise to T-cell malignancies in mouse model systems (15, 16).  
The immature pre T-cell receptor (pTCR) consists of a complex of alpha (pTCRα) and beta (TCRβ) 
peptide chains complexed with CD3δε and CD3γε heterodimers. Activation of this complex occurs 
through the SRC family kinase (SFK) members Lymphocyte Cell-Specific Protein-Tyrosine Kinase (LCK) 
and FYN. They are critical modulators of T-cell development and activation (17). LCK phosphorylates 
the plasma membrane associated TCR complex (18) and ZAP70 (19). ZAP70 in turn phosphorylates 
the linker for activation of T-cells (LAT) leading to the activation of downstream signaling cascades. 
The overall activity of LCK is regulated by the phosphorylation status of the activating and inhibitory 
tyrosine residues 394 and 505 respectively (20). LCK activation correlates with SRCY416 (also 
Y394
LCK
) phosphorylation, as the latter overrides the inhibitory effects of Y505 phosphorylation (21). 
We hypothesized therefore that T-ALL continues to rely on proliferative and survival stimuli inherent 
to the TCR signaling pathway, which, if inhibited, may enhance GC sensitivity. A targeted shRNA 
screen directed against components of the TCR signaling initiation complex identified a crucial role 
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for LCK in T-ALL proliferation, both in vitro and in vivo. The anti-proliferative effects of LCK 
knockdown could be replicated by using the small molecule inhibitor DAS. Drug synergy was 
observed using DAS in combination with DEX on patient derived xenograft (PDX) cell survival in vitro. 
Mirroring the design of early phase human trials, a murine phase II-like trial demonstrated 
significantly impaired leukemia progression in vivo using combination treatment. Our results present 
a clear rationale for using DAS in conjunction with DEX to enhance conventional chemotherapeutic 
treatment and revert glucocorticoid resistance in pediatric T-ALL patients. 
 
Methods 
Patient samples 
The patient derived material was collected as part of diagnostic investigations of patients at the 
Great North Children’s Hospital, Department of Paediatric Haematology and Oncology, Newcastle 
upon Tyne, United Kingdom. The material was collected and stored with informed consent obtained 
from all subjects in accordance with the Declaration of Helsinki.  
Samples with explicit written consent for in vivo studies were requested from the Newcastle 
Biomedicine Biobank, Newcastle University, United Kingdom and used according to approvals given 
by the Newcastle Biomedicine Biobank (NHB application NHB-008) and the local institutional review 
board Newcastle & North Tyneside Ethics Committee (REC reference: 07/H0906/109). 
Drug matrix assays 
Dasatinib (9 nM – 30 μM) (DC Chemicals, Shanghai, China) was titrated on T-ALL cell lines (4 x 
10
4
/well) in 96-well plates (Corning, NY, USA). Cell viability was assessed after 3 days using Cell 
Counting Kit 8 (NBS Biologicals, Cambridgeshire, UK). The absorbance was measured at OD450 nm 
using a POLARstar Omega plate reader (BMG LABTECH, Bucks, UK). IC
50
 values were determined by 
GraphPad Prism. Assays were performed in triplicate and at least 3 independent repeats were 
performed. 
For DAS/DEX combination treatments DAS (80 nM – 50 μM) and DEX (0.09 nM – 600 nM) were 
titrated in 2-dimensions on T-ALL cell lines (4 x 10
4
 cells / 96-well) or ex vivo expanded PDX cells (8 x 
10
4
 cells / 96-well). Ex vivo expansion was achieved after co-culture with OP9-DL1 for 1 week, after 
which cells were separated from their feeders by repetitive transfer and subsequently plated. After 
72h of culture, the plates were developed as above. Drug synergy was determined using Combenefit 
software (v2.021) (22).  
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Phase II-like Murine Trial 
For each of the 10 patient derived xenograft (PDX) samples, 8 x 10
6
 cells were intrafemorally (IF) 
injected into 4 NSG mice (40 mice in total) under isoflurane anesthesia. The 4 NSG mice derived from 
one PDX sample were matched for gender and age. T-ALL engraftment in mouse peripheral blood 
was monitored weekly by tail vein bleeds (20 μl blood/mouse). The four mice of each PDX were 
randomized to receive control vehicle, DAS (35 mg/kg), DEX (1 mg/kg) or DEX/DAS combination by 
intraperitoneal (IP) injection upon engraftment, defined as ≥0.5% peripheral blood hCD45+/hCD7+ 
cells. The median treatment duration of these mice was 15 days, depending on the clinical status. 
When any of the four mice displayed signs of ill health or weight loss, all four mice derived from this 
PDX were killed at the same time to assess leukemia engraftment in bone marrow, blood, spleen, 
liver and central nervous system (CNS). Spleen size and weight were recorded. Statistical analyses 
were performed using RStudio (MA, USA) with linear mix model. The final analysis excluded the 4 
mice derived from patient sample LK214, as all mice succumbed to T-ALL before treatment was 
initiated. 
See online supplemental file for further methods. 
Results 
A targeted shRNA screen of TCR pathway components identifies an essential role for LCK in T-ALL 
cell line and PDX proliferation in vitro 
To explore the importance of the pTCR/TCR signaling complex in proliferation and survival of 
malignant T-cells, we performed a limited shRNA screen targeting 6 genes with 3 shRNAs per gene, 
including LCK, ZAP70, PTCRA, FYN, CD3E and LAT in 4 T-ALL cell lines (HPB-ALL, CUTLL1, MOLT4, 
SUPT1), and included 18 control shRNAs (see Supplementary Methods)(Supplementary Table 1). In 
silico analysis, using the Cancer Cell Line Encyclopedia (CCLE), demonstrated that these 6 genes are 
highly expressed in a panel of T-ALL cell lines (Supplementary Figure 1A). LCK and PTCRA expression 
was confirmed by targeted gene expression analysis in T-ALL cell lines and patient samples (Figure 
1B)(Supplementary Figure 1B). The limited shRNA screen revealed the shLCK#3 construct targeting 
LCK was the only construct significantly depleted in all 4 cell lines, when compared with base line 
shRNA integration, underlining an important role for LCK in T-ALL cell line proliferation and/or 
survival (Figure 1A)(Supplementary Figure 1C-D). The shLCK#1, shZAP70#1 and shPTCRA#2 
constructs were lost in 3 out of 4 cell lines. Constructs targeting FYN, CD3E, or LAT were significantly 
depleted in one cell line only, suggesting that these molecules do not play an universal role in T-ALL 
cell proliferation. ShRNAs against essential ribosomal genes were predictably depleted, whilst all 3 
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shRNA constructs targeting the tumor suppressor PTEN were enriched as expected. Repeated 
sampling at 16, 30 and 40 days after transduction demonstrated progressive depletion of shRNA 
constructs targeting LCK and ZAP70 (Supplementary Figure 1E)(Supplementary Table 2). PDX LK203 
showed good viability (≥75%) and proliferation potential (Td = 2.8 days) in co-culture with human 
Mesenchymal Stem Cells (hMSC), hence subjected to shRNA screening. ShRNA sequencing 30 days 
after transduction confirmed all constructs targeting LCK were significantly depleted (Figure 
1A)(Supplementary Figure 1F)(Supplementary Table 3). 
 
Knockdown of LCK in T-ALL cell lines confirms an essential role for LCK in vitro propagation. 
To confirm the role of LCK and other components of the pTCR/TCR signaling complex in cell 
proliferation, competitive outgrowth assays were performed. SUPT1, MOLT4 and CUTLL1 cells were 
transduced with lentiviral shRNAs targeting LCK, ZAP70, FYN, PTCRA or non-targeting control 
shRNAs. Successfully transduced cells expressing green fluorescence protein (GFP) were seeded in a 
1:1 ratio with parental cells.  
Three shRNAs were used to silence LCK, of which shLCK#3 achieved the greatest degree of 
knockdown. Lentiviral knockdown with shLCK#3 led to significant reduction in mRNA in SUPT1 
(75%KD), MOLT4 (55% KD) and CUTLL1 (45% KD) cells (Figure 2A). Generally, greater knockdown was 
associated with more pronounced impairment of in vitro proliferation (Supplementary Figure 2A). 
LCK expression was confirmed at protein level, demonstrating ubiquitous expression of LCK in cell 
lines (Supplementary Figure 1G). In line with mRNA downregulation, knockdown of LCK led to 
decreased total LCK protein expression (Figure 2A). Non-transduced cells consistently outcompeted 
LCK knockdown cells resulting in a pronounced loss of over 70% transduced GFP
+
 cells in all 3 cell 
lines, underlining the critical and universal role of LCK in T-ALL cell line maintenance (Figure 2B-
C)(Supplementary Figure 2A, C).  
A similar, but less significant, observation was made for ZAP70 knockdown in SUPT1, MOLT4 and 
CUTLL1 cells. Efficient ZAP70 knockdown correlated with a pronounced proliferation defect 
(Supplementary Figure 2A, C). Knockdown of PTCRA affected proliferation in pTCRα
+
 MOLT4 and 
SUPT1, but not in pTCRa
_
 CUTLL1 (Supplementary Figure 2A, C). Moreover, FYN knockdown did not 
affect proliferation in any of the cells lines despite efficient knockdown (Supplementary Figure 2B). 
 
Knockdown of LCK in T-ALL cell lines and PDX samples impairs leukemia propagation in vivo. 
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To confirm a functional role for LCK in vivo, PDX L963 cells were transduced with our shRNA library 
and transplanted into 6 NSG mice (Figure 3A)(Supplementary Figure 3A). Genomic DNA (gDNA) was 
extracted from L963 cells isolated from bone marrow and spleen after mice became symptomatic 
(week 11). ShRNA sequencing indicated that shLCK#3 represented the most significantly depleted 
shRNA construct in vivo (Figure 3A)(Supplementary Figure 3B)(Supplementary Table 3). 
To assess the effect of LCK knockdown on engraftment fitness, MOLT4 cells were transduced with 
lentiviral vectors encoding either red fluorescent protein RFP/shNTC (non-targeting control) or 
GFP/shLCK#3. Equal proportions of cell populations were transplanted into NSG mice (n = 5). 
Leukemia cells were isolated from spleen, bone marrow and liver once mice were symptomatic (day 
26). Flow cytometric analysis of the leukemic cell population established that cells carrying shNTC 
had a clear competitive engraftment advantage over cells with LCK knockdown in all mice tissues 
sampled (Figure 3B)(Supplementary Figure 3C). 
 
Knockdown of LCK leads to cell cycle arrest in T-ALL cell lines and PDX samples 
Next we investigated the mechanisms underlying the defect in proliferation, survival and 
engraftment observed after LCK knockdown. Jurkat, MOLT4 and SUPT1 cells were transduced with 
shLCK#1/#3 and cell cycle analyses performed. In all cell lines, we observed significant cell cycle 
arrest with an increase in G
0
/G
1
 phase and decrease in S phase after LCK knockdown (Figure 4A-C) 
(Supplementary Figure 4A). 
ShLCK#3 led to decreased protein levels of total LCK and activated p-Y416
SRC
 in cell lines, suggesting 
activation status of LCK is associated with cell cycle arrest. In PDX L963, LCK knockdown led to a 45% 
reduction in total LCK expression, as well as 71% reduction in p-Y416
SRC
 as assessed by Phosflow 
(Figure 4D). This knockdown resulted in a decrease in S phase over time compared to control 
(Supplementary Figure 4B). The proliferative behavior of PDX cells was analyzed after labeling with 
cell trace violet (CTV). PDX L963 cells were transduced with shRNA constructs targeting LCK or a non-
targeting control (NTC) and co-cultured with OP9-DL1 feeder cells for 13 days. The LCK knockdown 
cells showed restricted proliferation compared to the control cells (Figure 4E). Confirmatory siRNA 
knockdown of LCK was undertaken in PDX samples LK203 and L963. Knockdown of total and 
activated LCK was confirmed by Phosflow. Corroborating our earlier findings, cell cycle arrest was 
observed (Supplementary Figure 4C-D).  
Knockdown of LCK was analyzed for early apoptosis induction in CUTLL1, MOLT4, SUPT1 and Jurkat. 
Although a clear increase in Annexin V staining was observed in MOLT4, suggesting LCK knockdown 
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led to apoptosis, this was not observed in CUTLL1, Jurkat or SUPT1 (Supplementary Figure 4E). This 
suggests that cell cycle arrest, rather than apoptosis induction, is the predominant effect leading to 
diminished cell expansion in vitro and reduced propagation in vivo after LCK knockdown. 
 
The tyrosine kinase inhibitor DAS blocks LCK function and leads to cell cycle arrest. LCK activation 
levels predict response to LCK inhibition. 
The tyrosine kinase inhibitor DAS is a dual SRC/ABL inhibitor known to effectively inhibit LCK (21). 
The effect of DAS on LCK protein expression and activation status was assessed by Western Blot, 
after demonstrating near universal LCK activation as evidenced by tyrosine residue 416 
phosphorylation in cell lines (Supplementary Figure 1G). We confirmed that DAS effectively 
abolished activated p-Y416
SRC
 in all 4 T-ALL cell lines tested, whilst slightly decreasing total LCK 
protein levels. Furthermore, dephosphorylation of inhibitory p-Y505
LCK
 was noted, as well as a 
decrease in p-Y783
PLCγ1 
and p-Y493
ZAP70
, two downstream targets of LCK (Figure 5A)(Supplementary 
Figure 5A). As knockdown of LCK leads to cell cycle arrest, we performed cell cycle analyses after 
administration of DAS.  Cell cycle arrest was observed in all 6 T-ALL cell lines tested, with a significant 
increase in G
0
/G
1
 and decrease in S phase (Figure 5A)(Supplementary Figure 5B). In parallel, PDX cells 
supported by in vitro co-culture with OP9-DL1 were exposed to DAS. In line with our cell line data, 
DAS abolished activated p-Y416
SRC
 levels in all 6 PDX samples (Figure 5B)(Supplementary Figure 5C) 
and cell cycle arrest was observed in all 3 PDX samples tested (Figure 5B)(Supplementary Figure 5D). 
The in vitro sensitivity of a panel of 9 T-ALL cell lines to DAS was determined. The IC
50
 observed 
ranged from 5 nM (HSB2) to 15 µM (MOLT16) (Figure 5C). The cell line HSB2 not only demonstrated 
the highest sensitivity to DAS but also the highest p-Y416
SRC
 activation level as determined by 
Phosflow. This observation can be explained by the presence of a t(1;7)(p34;q34) translocation 
leading to LCK activation by T cell receptor beta (TRB) enhancer elements in HSB2. We thus 
hypothesized that the level of activated LCK might represent a biomarker for DAS responsiveness. 
Phosflow was used to quantify and calculate the ratio between p-Y416
SRC
 and total LCK. A strong and 
significant correlation was observed between the IC
50
 for DAS and the ratio of activated Y416
SRC
 in T-
ALL cell lines (R
2
=0.778, p=0.004) (Figure 5C). The sensitivity of PDX cells to DAS ranged from GI
50
 of 
23.8 nM to 19.7 µM (median of 1.2 µM). However, in this setting, no significant correlation between 
the GI
50 
and p-Y416
SRC
/LCK ratio was identified, suggesting that DAS sensitivity of patient-derived 
cells is dependent on additional factors (Supplementary Figure 5E). 
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DAS re-sensitizes DEX resistance in T-ALL cell lines and PDX samples 
DAS leads to complete inhibition of p-Y416
SRC
 and cell cycle arrest in T-ALL cell lines and PDX cells, 
suggesting that DAS treatment of T-ALL has a cytostatic effect. In clinical practice, effective 
eradication of T-ALL relies on the application of combinatorial treatment. LCK inhibition has 
previously been shown to sensitize chronic lymphoid leukemia (CLL) to DEX and induce cell death 
(23). We thus went on to investigate potential synergy between LCK inhibition and DEX, as DEX is 
universally used for treatment of ALL. The cell viability of SUPT1 and CUTLL1, in the presence of DEX, 
was evaluated after knockdown of LCK. Whereas the cell viability of mock transduced and non-
targeting control cells was minimally affected by DEX treatment, LCK knockdown increased DEX 
sensitivity suggesting that LCK protein and/or activity levels play a crucial role in glucocorticoid 
resistance (Figure 6A)(Supplementary Figure 6A).  
A more detailed analysis of the potency of the combination of DEX and LCK inhibition was examined 
by using DAS instead of the LCK knockdown. DEX (0-600 nM) and DAS (0-50 µM) were titrated along 
a dose matrix and cell viability was determined. Synergy for individual drug combinations was 
determined using Combenefit (22). The matrix revealed drug synergy at concentrations which are 
clinically achieved, i.e. 100 nM for DEX and 264 nM for DAS (Figure 6B)(Supplementary Figure 6B) 
(24, 25). Bioinformatic analysis of all 10 T-ALL cell lines revealed a statistically significant enrichment 
of drug synergy at clinically relevant concentrations. This synergy was observed at 8-110 nM of DEX 
and 0.223-4.5 µM of DAS (Supplementary Figure 6C-D).  
Subsequently, PDX cells were expanded ex vivo for 1 week and exposed to the same drug 
combinations in dose matrices. These assays verified the synergistic action of DEX+DAS in a wide 
range of PDX cells, whilst confirming that increased DAS concentrations and resultant LCK inhibition 
augmented the response to DEX (Figure 6C)(Supplementary Figure 6E). Combined analysis of all drug 
matrices with PDX cells again revealed a statistically significant enrichment of drug synergy at 
clinically relevant concentrations (Supplementary Figure 6F). Moreover, the combination of 
DEX+DAS induced more cell death compared with control vehicle or single drugs as revealed by 
Annexin V/PI staining (Figure 6C). 
DEX has a wide range of actions, including genomic and non-genomic effects. Genomic effects are 
the result of nuclear translocation of the glucocorticoid receptor and subsequent transactivation or 
repression of genes containing a glucocorticoid response element (GRE), as exemplified by the 
Glucocorticoid-Induced Leucine Zipper (GILZ) gene. Accordingly, we observed strong induction of 
GILZ gene expression after DEX exposure in the T-ALL cell line Jurkat and 5 PDX samples tested 
(Figure 6D)(Supplementary Figure 6G). This response was significantly enhanced when combining 
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DEX with knockdown of LCK (Figure 6D) or DEX+DAS in a range of T-ALL cell lines and PDX samples, 
suggesting that LCK inactivation augments DEX-induced gene transcription and reverses DEX 
resistance (Figure 6D)(Supplementary Figure 6G). 
 
Phase II-like trial in vivo demonstrates significant reduction in leukemia burden after combination 
treatment with DEX and DAS  
To test the efficacy of DEX and DAS in vivo, we conducted a phase II-like trial in mice (Figure 7A) (26). 
Ten PDXs were engrafted in 4 mice each. The 4 mice derived from 1 single patient sample were 
randomly assigned to treatment arms, namely control vehicle, DEX (1 mg/kg), DAS (35 mg/kg) or 
DEX+DAS (1 mg/kg DEX + 35 mg/kg DAS). After IF injection, mice tail vein blood was monitored 
weekly for human CD7/CD45 and murine CD45 expression to monitor peripheral blood engraftment. 
Representative PDX L809 commenced treatment 46 days after injection for a total duration of 3 
weeks; the 4 mice were culled 72 days after injection (Figure 7B). L809 cells engrafted in the spleens 
of the 4 mice showed greatly reduced levels of total LCK and dephosphorylation of LCK (p-Y416
SRC
 
and p-Y505) after DAS or DEX+DAS combination treatment (Figure 7C). Western analysis of positively 
selected viable human cells again demonstrated decreased protein expression of LCK and p-Y416
SRC
 
after DAS treatment. The number of residual viable human cells after effective DEX+DAS treatment 
was not sufficient to categorically confirm reduced protein expression (Supplementary Figure 7F). 
One mouse in DAS arm (LK080) developed uterine prolapse before dosing commenced and the mice 
derived from PDX LK214 succumbed during first week of treatment. These 5 were excluded from 
final analysis. Combining the results of 35 mice derived from 9 patient samples, DEX+DAS treatment 
significantly impaired leukemia progression more than single drug DEX, DAS or control vehicle as 
measured by hCD45 or hCD7 engraftment in peripheral blood, bone marrow, spleen and CNS (Figure 
7D-F)(Supplementary Figure 7A). Single agent DEX reduced CNS leukemia burden in 7/9 samples, 
reflecting its proven efficacy in reducing CNS relapses (27), whilst DAS showed some reduction in 
CNS burden in 4/8 samples (Supplementary Figure 7B). Combination therapy was particularly 
effective, with complete eradication of measurable CNS leukemia in 5 patient samples and evidence 
of an additive effect with DEX in 3 out of 4 of the remaining patient samples (Supplementary Figure 
7B). When considering the cohort of nine patient samples overall, combination treatment 
significantly reduced leukemic infiltrates compared to control (p=0.02). Representative histology 
images are shown in Figure 7G. Spleen weight was substantially reduced in mice receiving 
combination treatment, compared with the single or control treatment arms (Supplementary Figure 
7C-D). DEX+DAS also significantly reduced hCD45
+
 or hCD7
+
 leukemia cell engraftment in liver tissue 
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of all 6 PDX samples analyzed (Supplementary Figure 7E). The initial therapeutic advantage of 
DEX+DAS in mice derived from PDX LK080 was lost at the end of the experiment, most likely because 
these mice were kept alive for 3 weeks after completion of treatment. In the case of L907 however, 
the benefit of combination treatment was not observed until the last time point (Supplementary 
Figure 7G). 
  
Discussion 
Using a phase II-like murine trial, we demonstrate here the efficacy of the drug combination 
DEX+DAS in impairing expansion of human T-ALL samples. This effect is apparent in an unselected, 
biologically heterogeneous, cohort of PDX samples. This trial format recapitulates early phase 
human clinical trials and indicates that this drug combination could be widely applicable in the 
treatment of T-ALL. Studies by Serafin et al first proposed a role for this drug combination (28). Our 
murine trial extends these initial observations with an extensive cohort consisting of 9 different PDXs 
demonstrating treatment advantage for both DEX sensitive and resistant T-ALL. 
Significant superiority of DEX+DAS was demonstrated even after exclusion of mice, who reached 
their clinical end points prematurely. These untoward events highlight the practicalities of 
performing murine trials.  
We propose that the impaired in vivo expansion results from a combination of cell cycle arrest as 
well as cell death. Several mechanisms could provide plausible explanations for the occurrence of 
cell cycle arrest. DAS is a protein tyrosine kinase inhibitor which targets Abl and SFK family members. 
We have confirmed that DAS effectively inhibits activity of the SFK member LCK by preventing 
phosphorylation, leading to G
0
/G
1
 arrest. DAS has previously been shown to inhibit cyclin dependent 
kinase 1 (CDK1), which plays a central role in G
1
/S and G
2
/M transition (29). Furthermore, G
1
 cell 
cycle arrest, through upregulation of the cyclin-dependent kinase inhibitors p21
CIP1
 (CDKN1A) and 
p27
KIP1
 (CDKN1B), has been observed after DAS treatment in AML (30). We propose that LCK is the 
predominant target of DAS in this disease setting, as our shRNA screen identified a critical role for 
LCK in cell proliferation in cell lines and PDX samples. Moreover, LCK is the proposed DAS target 
when blocking T-cell activation (21). Competitive assays confirmed defective proliferation of T-ALL 
cells after LCK knockdown in vitro and in vivo. We have shown that LCK knockdown leads to G
0
/G
1
 
cell cycle arrest in cell lines and PDXs. This effect was more pronounced using DAS, a finding which 
could potentially be explained by incomplete knockdown of LCK or the wide spectrum of kinases 
targeted by DAS. 
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As reported earlier and confirmed in our studies, DAS is cytotoxic to a small subset of T-ALL samples 
with IC
50
 values in the low nanomolar range (31). These observations were made in T-ALL samples 
without kinase activating mutations, which are seen very infrequently in T-ALL. To the best of our 
knowledge, our cohort includes only one PDX with such an activating genetic lesion (LK287, FIP1L1-
PDGFRA). Cytotoxicity to DAS is significantly increased upon combination with DEX. Our data 
indicate drug synergy between DAS and DEX at clinically relevant concentrations. A previous, mostly 
in vitro, study advocated the use of DEX+DAS in GC resistant T-ALL (28). Our extended studies 
indicate DEX+DAS act synergistically in the majority of cell lines and PDXs tested independent of 
their prior sensitivity to DEX. The potential of DEX+DAS to revert GC resistance is an exciting 
observation. GC resistance is frequently observed in relapsed / refractory T-ALL (4), and DEX+DAS 
provide a clinically actionable approach to re-sensitize T-ALL resistant to DEX. 
The implementation of DAS into clinical management would benefit from the identification of a 
reliable response biomarker. Although LCK activation status (ratio p-Y416
SRC
/LCK) strongly correlates 
with DAS sensitivity in cell lines, we were unable to corroborate this observation in PDX cells. Sample 
size and intricacies of in vitro assays using PDX cells could provide possible explanations for these 
inconsistencies. Nevertheless, in vivo drug synergy was observed in the majority of samples tested. 
Of interest, drug response profiling of T-ALL samples suggested SRC pathway activation may 
represent a response biomarker (31).  
The mechanism underlying the observed drug synergy remains to be fully elucidated. T-cell 
activation can be blocked by using clinically relevant concentrations of the tyrosine kinase inhibitor 
DAS, which binds to the ATP-binding pocket of LCK thereby preventing the phosphorylation of the 
activating loop of the kinase domain p-Y416 (21, 32). When DEX is combined with DAS, physiological 
CD3+ T-cell proliferation is reduced in an additive way (33, 34). Furthermore, it has been previously 
suggested that the Calcineurin/NFAT/IL-4 axis is activated in patients exhibiting a prednisone poor 
response (28). We have shown here that combination of DEX+DAS significantly increases GILZ gene 
expression, reflecting increased transcriptional activity of the GC receptor. We thus hypothesize that 
inhibition of LCK disrupts the TCR-GR complex and established crosstalk between the TCR and GR 
pathways leading to dissociation and transcriptional activation of the GR (13).  
To conclude, drug resistant T-ALL continues to represent an unmet clinical need. We provide further 
support for the inclusion of DAS in the treatment of T-ALL. It has been reported that DAS in 
combination with conventional chemotherapy is safe and well tolerated in children and young 
adults, although hematologic toxicity was significant (35). Thus, the DEX+DAS combination should be 
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considered in early phase setting to evaluate toxicity and efficacy in patients with GC resistant 
disease with or without cerebral spinal fluid (CSF) involvement. 
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Figure Legends 
 
Figure 1. A targeted shRNA screen reveals LCK is essential for in vitro proliferative potential. (A) T-
ALL cell lines (SUPT1, MOLT4, HBP-ALL, CUTLL1) and PDX LK203 were subjected to a functional 
screen using a pLKO5-shRNA library containing 36 constructs targeting selected pTCR/TCR signaling 
complex components (PTCRA, CD3E, FYN, ZAP70, LCK, LAT), positive (PTEN, RPS29, RPL9), negative 
controls (KLHL7, CD19, DDB2, ERGIC3, FLG, RUNX1-ETO, SESN2, TRPM7) and a non-targeting control 
(NTC). Genomic DNA was sampled and barcoded. Enriched and depleted shRNAs were identified by 
next generation sequencing (NGS). The heatmap depicts statistically significant gains (red) or losses 
(green) of shRNA constructs after in vitro culture of 4 T-ALL cell lines (40 days) and PDX LK203 (30 
days). (B) Relative gene expression of LCK in 7 cell lines and 12 PDX samples. LCK expression was 
determined in 4 T-ALL cell lines, 697 and REH (B-lineage ALL cell lines), TK6 (lymphoblastoid cell line) 
and 12 PDX samples by real time qPCR. GAPDH served as reference gene for normalization. 
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Figure 2.  Knockdown of LCK reduces propagation of T-ALL cell lines in vitro. SUPT1 (A and B) and 
MOLT4 (A and C) cells were lentivirally transduced with shNTC (non-targeting control), shLCK#1, 
shLCK#2, shLCK#3, shPTCRA#1, or shZAP70#1 expression constructs. (A) Knockdown efficiency of LCK 
at mRNA level (left) and protein level (right) after 6 days. Whole cell lysates were probed for total 
LCK and GAPDH in Western Blot analysis. (B, C) T-ALL cell lines SUPT1 (B) and MOLT4 (C) transduced 
with GFP-expressing shLCK (blue), shZAP70 (purple),  shPTCRA (red) or shNTC (black) constructs were 
seeded in a 1:1 ratio with non-transduced parental cells in vitro. Cells were cultured and analyzed 
repetitively by flow cytometry for the presence of GFP+ cells over a time period of 30 and 40 days 
for SUPT1 and MOLT4, respectively. A relative GFP expression of 1 denotes a mixture of 50% GFP+ 
cells with 50% parental cells (ratio 1:1). A value of 0.5 refers to 25% of GFP+ cells and 75% parental 
cells (ratio 1:4).  Student t-test; *p<0.05, ** p<0.01, *** p<0.005, **** p<0.001. 
 
Figure 3. Loss of LCK negatively effects propagation potential of the T-ALL cell line MOLT4 and PDX 
L963 in vivo. (A) Volcano plot derived from the functional in vivo screen representing the magnitude 
of the fold change (log2) in shRNA abundance derived from leukemia cells isolated from the spleen 
of PDX L963 on the x-axis. Each dot represents an individual shRNA construct. The y-axis represents 
the significance in enrichment or depletion of shRNA constructs (log10 scale). 3 dots (shLCK#3, 
shRPL9#1 and shCD19#2) above the blue line are significantly depleted (p<0.05). Bar plot of the 
normalized shLCK#3 sequencing reads (log2) in leukemic cells derived from the bone marrow 
(orange) or spleen (blue) of 6 individual mice (M1-6), relative to the frequency of these reads before 
transplantation (green, base line B1-3). (B) Schematic representation of the in vivo competitive 
outgrowth assay. MOLT4 cells were lentivirally transduced with shNTC (red fluorescent protein, RFP) 
or shLCK#3 (GFP) and intrafemorally injected into 5 NSG mice in a 1:1 ratio. Mice were culled once 
symptomatic and the ratio of RFP : GFP positive human leukemic cells in spleen (n=5), bone marrow 
(n=3) or liver (n=3) determined by flow cytometry. In all mice the MOLT4 cells carrying shLCK#3 were 
outcompeted by shNTC cells during engraftment in spleen, marrow and liver. Student t-test; 
*p<0.05, ** p<0.01, *** p<0.005, **** p<0.001. 
 
Figure 4. LCK knockdown leads to cell cycle arrest in T-ALL cell lines and PDX cells. (A - C) Cell cycle 
status was determined by flow cytometry using Hoechst 33342 in cell lines Jurkat (A, C), MOLT4 (B, 
C) and SUPT1 (C) 7 days after transduction with shLCK#3 or shNTC expression vectors. (D) PDX L963 
cells were lentivirally transduced with shLCK#3 or shNTC expression constructs. Phosflow analysis of 
total LCK and p-Y416
SRC
 was performed 8 days later. (E) shLCK#3 and shNTC transduced PDX L963 
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cells were loaded with CTV and cultured for 13 days. Flow cytometric analysis of CTV incorporation 
(cell divisions) was performed and demonstrated progressive reduction in cell number after 4-6 cell 
divisions after LCK knockdown relative to control knockdown. Student t-test; *p<0.05, ** p<0.01, 
*** p<0.005. 
 
Figure 5. DAS inhibits LCK and leads to cell cycle arrest. (A) SUPT1 and MOLT4 cells were treated 
with vehicle control or DAS (2 µM) for 24 h and expression of total LCK, activated p-Y416
SRC
, total 
PLCy1 and activated p-Y783
PLCγ1
 was assessed in Western Blot analysis (left) or cells were stained 
with Hoechst and analyzed for cell cycle status (middle and right). (B) PDX LK203 and L963 cells were 
treated for 24 h with 1 µM of DAS. LCK and PLCγ1 total protein and activating phospho-sites at Y416 
and Y783 were assessed in Western Blot analyses or PDXs were stained with Hoechst and analyzed 
for cell cycle status. (C) The in vitro sensitivity of a panel of T-ALL cell lines to DAS was investigated 
and IC
50
 calculated. Phosflow was used to determine the ratio of activated p-Y416
SRC
 / total LCK. This 
ratio was correlated with in vitro sensitivity to DAS (R
2
=0.778, p=0.004). Student t-test; *p<0.05, ** 
p<0.01. NB HSB2 was excluded from this analysis, as the extreme sensitivity to dasatinib was caused 
by the presence of a unique translocation absent in all other sensitive cell lines.  
 
Figure 6. DEX and DAS act synergistically to induce cell death in T-ALL. (A) Cell viability of parental 
SUPT1 cells (mock), shCtrl (NTC), shLCK#1 or shLCK#3 transduced SUPT1 cells upon treatment with 
increasing DEX concentrations (0-1699 nM). (B) Cell viability of SUPT1 with and without DAS (left; 
black line, no DAS; blue line, 0.4 µM; red line, 2.0 µM) in combination with increasing concentrations 
of DEX (0-600 nM) as derived from the drug matrix with titration of DEX (0-600 nM) and DAS (0.08-
50 uM; right). (Right) Combenefit analysis of drug matrix demonstrates drug synergy in SUPT1 cells 
at clinically relevant drug concentrations. (C) (Left) LK203 cells were expanded ex vivo on OP9-DL1 
feeder cells for 1 week prior to treatment with and without DAS (black line, no DAS; blue line, 0.08 
µM; red line, 2.0 µM; orange line, 10 µM) in combination with increasing concentrations of DEX (0-
600 nM) as derived from a drug matrix with DEX (0-600 nM) and DAS (0.08-50 uM)(Supplementary 
Figure 6E). (Right) Cell death analysis in LK203 cells exposed to control (Ctrl) conditions, DAS (1 µM), 
DEX (100 nM) or DAS+DEX combination treatment. (D) (Left) Normalized GILZ mRNA expression in 
Jurkat cells after transduction with shNTC or shLCK#3 with or without DEX exposure (100 nM). 
(Right) Normalized GILZ mRNA expression in Jurkat cells after exposure to control (Ctrl) conditions, 
DAS (2 µM), DEX (100 nM) or DAS+DEX combination treatment at the same concentrations. Student 
t-test; *p<0.05, ** p<0.01, *** p<0.005, **** p<0.001. 
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Figure 7. DEX + DAS synergize to impair leukemia engraftment in a Phase II-like murine trial. (A) 
Layout of the in vivo trial using 10 different PDX samples. PDX samples were engrafted into 4 mice 
each and treated with control vehicle (Ctrl), DEX (1mg/kg), DAS (35mg/kg) or DEX+DAS (1mg/kg DEX 
+ 35mg/kg DAS). Mice were dosed once daily, 5 times per week, for 2 – 3 weeks depending on 
clinical status of the mice. (B) Engraftment of hCD45+ cells (%) was determined weekly in peripheral 
blood derived from 4 mice injected with PDX L809. Engraftment levels are shown starting from day 
of injection (day 0) in mice receiving control vehicle (Ctrl, black), DAS (blue), DEX (green) or DEX+DAS 
(red). The vertical dotted lines indicate the treatment window (3 weeks) starting on day 46 and 
completing on day 64. Mice were culled on day 72 and analyzed for hCD45/hCD7 engraftment. (C) 
Western blotting of total and phosphorylated LCK protein levels of whole cell lysates derived from 
the spleens of 4 mice injected with PDX L809 under 4 different treatment arms (Ctrl, DAS, DEX or 
DEX+DAS) relative to the housekeeper GAPDH. (D - F) Summary of final human CD7+ engraftment 
(%) in peripheral blood (D), spleen (E) and bone marrow (F) of mice treated with Ctrl (black), DAS 
(blue), DEX (green) or DEX+DAS (red). Significance levels;*p<0.05, ** p<0.01, *** p<0.001. (G) 
Photomicrographs of whole brain-skull sections stained with hematoxylin and eosin from PDX L809. 
(Left) Low power scout view of whole brain with area shown in all other images marked by black 
box. (Centre and Right) High power view (x20 objective) of meninges around the central venous 
sinus in mice receiving Ctrl, DAS, DEX or DEX+DAS treatment. Red arrows mark the leukemic 
infiltrate. Scale bar marks 1mm on scout view and 100µm on high power images. 
 







T-ALL cell lines and Tissue Culture 
The cell lines used were available in-house, or kindly gifted by Dr M Mansour, UCL Cancer Institute, 
London, UK (ALL-SIL, CUTLL1, KOPTK1, MOLT16, DU.528, Loucy). All cell lines were authenticated 
before use. SUPT1, CUTLL1, MOLT4, Jurkat, HPB-ALL and CCRF-CEM were cultured in RPMI1640 with 
10% fetal bovine serum (FBS; Thermofisher). HSB2, KOPTK1, ALLSIL, DU528 and MOLT16 were 
cultured in RPMI1640 with 20% FBS. 293T was cultured in DMEM with 10% FBS, 2 mM L-Glutamine 
and 1 mM Sodium Pyruvate (Sigma#S8636, Dorset, UK). The murine OP9-DL1 cell line was kindly 
provided by JC Zuniga-Pflucker, Toronto, Canada, and cultured in MEMα (ThermoFisher) with 10% FBS. 
Cell culture media and additives were obtained from Sigma unless stated otherwise. 
Xenotransplantation of patient samples 
Patient-derived xenografts (PDXs) were harvested from the NOD.Cg-PrkdcscidIl2rgtm1wjl/SzJ (NSG, 
Charles River labs and bred in-house) mice after the engraftment of patient samples. PDXs were co-
cultured ex vivo with OP9-DL1 in StemSpan Serum-Free Expansion Medium II (STEMCELL, UK) 
supplemented with human IL-7 (10 ng/ml) and SCF (100 ng/ml) (both PeproTech, UK). 
Lentivirus Production and Cell Transduction 
Lentivirus was generated in 293T cells, seeding 1 x 106 cells per 10 cm plate (Corning, USA) by co-
transfection with a second-generation lentiviral vector pMD2.G and pCMV ΔR8.91. For co-
transfection, 5 μg pMD2.G, 15 μg pCMVR Δ8.91 and 20 μg of lentiviral vector were mixed to a final 
volume of 500 μl containing 0.25 M CaCl2. This solution was slowly mixed with 500 μl 2xHeBS (0.28 M 
NaCl, 0.05 M HEPES, 1.5mM Na2HPO4, pH 7.0) drop by drop. After thorough mixing, the mixture was 
left for 30-40 mins at room temperature. The 1 ml transfection mix was gently dropped onto a 293T 
monolayer of 25-35% confluency. On the 3rd day, after aspirating the 293T medium, the cells were 
carefully washed once with PBS and fresh cell culture medium was added. After culturing the cells for 
72 hours, the supernatant containing lentivirus was harvested and filtered through a 0.45 μM Syringe 
Filter (StarLab, UK). 
The filtered supernatant of 293T containing the lentivirus was either added directly to T-ALL cells or 
concentrated prior to improve transduction efficiency. Lentivirus was centrifuged by ultra-centrifuge 
centrifugation (Beckman Coulter Optima XE-100, IN, USA) at 26,500 x g for two hours and re-
suspended in an appropriate volume of 100ul – 1 ml cell culture medium. Cells were seeded in 48-well 
plates at 1 – 2 x 106 cells per well and transduced in presence of 0.1% polybrene (8 µg/ml) by spin-
fection at 900 x g for 50 mins. After spin-fection the cells were cultured and the next day the majority 
of the lentiviral and polybrene containing supernatant was removed from the cells, before addition of 
fresh media and transfer of cells to a 24-well plate. 5 - 6 days post transduction, the transduction 
efficiency was measured by flow cytometry. 
Targeted shRNA Screen 
A library of short hairpin RNA (shRNA) targeting PTCRA, LCK, FYN, ZAP70, CD3E and LAT was generated 
using the pLKO5d.SFFV.eGFP backbone (kindly provided by Dirk Heckl and Jan-Henning Klusmann, 
MHH Hannover 1 (Supplementary Table S3). Positive and negative controls comprising 18 shRNAs were 
selected based on in-house shRNA screens in a variety of cancers. ShRNA oligonucleotides (Sigma-
Aldrich, UK) were annealed by heating to 95°C for 5 min and slow cooling to room temperature. ShRNA 
oligonucleotides were ligated into the Bsm1 restriction enzyme side of pLKO5d.SFFV.eGFP vectors. 
Sequences were verified using Sanger sequencing (Source Bioscience, UK). 
T-ALL cell lines and PDX cells were transduced to an MOI≤0.3. In PDX LK203 and L963, a transduction 
efficiency of 7% and 3% respectively was obtained. Samples were collected at baseline, day 16, 30 and 
40 for the in vitro screen and at baseline and endpoint for the in vivo screen. Cells were intrafemorally 
injected into NSG mice and harvested once mice began to exhibit clinical signs. Genomic DNA (gDNA) 
was extracted using the DNeasy Blood & Tissue Kit (Qiagen, UK) and quantified by Nanodrop ND-1000 
(Thermo Scientific, UK), after which 825 ng was amplified with barcoding primers (Supplementary 
Table S2) by 30 cycles of PCR using Phusion Hot Start II DNA Polymerase (ThermoFisher#F549L, Paisley, 
UK). The resulting amplicons were sequenced by next generation sequencing (NGS) (Illumina MiSeq) 
at Newcastle University Genome Core Facility and analyzed by the Bioinformatic Support Unit 
(Supplementary Table S1 and S2).  
Next Generation Sequencing and analyses 
Raw sequencing reads were trimmed at both ends up to the locations of barcode sequence before 
aligning to the reference shRNA barcodes using Bowtie2 2 with a zero mismatch tolerance. An in-house 
script was used to extract read counts from aligned sequence files. Differential representation 
analyses of aligned read counts from different screen datasets were performed as described in Dai et 
al. using edgeR 3,4.  In brief, read counts were normalized to adjust for library size differences across 
samples. The likelihood ratio test method based on generalized linear models (GLM) framework in 
edgeR was used to test for differential representation of shRNA barcodes.  
For screen data from cell lines, time-course differential representation analysis with replicates was 
performed in order to identify shRNAs with changes in their abundance over time (days 0, 16, 30 and 
40). The analysis was performed for each cell line independently. Depletion of shRNAs over time was 
allocated a negative slope of the regression line, whereas enrichment of shRNAs was allocated a 
positive slope. 
For the primograft LK203 in vitro screen dataset, we treated samples from different time points (day 
16 and day 30 with/without mesenchymal stem cell MSC) as non-baseline samples and tested for 
differential representation between the baseline samples and non-baseline samples.  
To control for unwanted variation (e.g. biological, technical) between samples derived from the in vivo 
screen dataset, the RUVg approach was employed to estimate factors of unwanted variation under 
the assumption that our negative controls (i.e. non targeted control (NTC) and shRNA targeting 
RUNX1/ETO) had constant representation across samples 5. 
To adjust for this unwanted bias, the estimated factors of unwanted variation as well as the covariate 
of interest were both included in the model for differential representation analysis which was 
performed on upper-quartile normalized counts using the GLM approach from edgeR as described 
above. In this dataset, we tested for differential representation between baseline samples and 
samples either from spleen or bone marrow separately. 
Flow cytometry 
For PhosFlow, 1 x 106 cells were washed with cold PBA (PBS, 1% BSA and 0.05% NaN3), fixed in Cytofix 
Fixation Buffer (BD Bioscience) for 15 mins at 37°C, washed and permeabilized in PermBuffer III (BD 
Biosciences) for 30 mins on ice. For control and specific staining, mouse serum (Sigma Aldrich#M5905), 
PE-IgG1 control (R&D#IC002P, clone 11711), Alexa Fluor 647-IgG control (Biolegend#400130, clone 
MOPC-21), Alexa Fluor 647-LCK (BioLegend#628303, clone LCK-01) and PE-Src (Y418) (BD 
Biosciences#560094, clone K98-37) were used. 
Cell cycle analysis was performed using propidium iodide or Hoechst 33342 (both Sigma Aldrich). 
Apoptosis assay was performed using PE-Annexin V/7-AAD (BD Biosciences) as per manufacturer’s 
instructions or APC-Annexin V (Biolegend)/LIVE-DEAD Fixable Aqua (ThermoFisher). 
Peripheral leukemia engraftment was assessed by incubating mouse blood with APC-huCD45 (HI30), 
PE-huCD7 (M-T701) and BV421-mCD45 (30-F11) (all from BD Biosciences) for 20 mins in the dark. Red 
cells were lysed using freshly prepared lysis buffer (155 mM NH4Cl, 12 mM NaHCO3, 0.1 mM EDTA) 
for 10 mins. Cells were stained for cell viability with LIVE/DEAD Fixable Aqua prior to fixation in 2% 
paraformaldehyde. 
For PDX proliferation assays, PDXs were incubated with 5 μM Cell Trace Violet (CTV) 
(ThermoFisher#C34571, Paisley UK) for 20 mins at 37°C. Cell loading was stopped using FBS (10% final), 
cells were washed in PBS and reseeded in SFEM II medium with OP9-DL1 cells. Two weeks later, cells 
were separated from feeder cells by repetitive transfer of leukemic cells. BD FACSCantoTM II was used 
to assess CTV distribution at the excitation/emission of 405/450. Flow cytometry was performed on 
BD Calibur or BD LSRFortessaTM X-20 Attune NxT (ThermoFisher) and raw data were analysed by 
Flowjo (v10, Oregon, USA). 
Competitive Assay 
In vitro T-ALL cells (1 x 106) were transduced with shRNA viral supernatant (500 μl). Transduction 
efficiency as demonstrated by GFP expression was determined at day 6. Five million cells were equally 
mixed with parental cells to generate approximately 50% GFP expression. Cells were kept in fresh 
medium and the GFP expression was assessed every three days. A relative GFP expression of 1 denotes 
a mixture of 50% GFP+ cells with 50% parental cells (ratio 1:1). Graphs were generated by using 
GraphPad Prism (version 6, CA, USA). 
For the in vivo competitive assay MOLT4 cells were transduced with either pLKO5RFP657-shNTC 
(kindly provided by O Heidenreich) or GFP-shLCK#3 (see section Targeted shRNA screen). The cells 
were then mixed to give a 1:1 ratio of RFP : GFP. 1 x 107 cells were injected into 5 NSG mice. 26 days 
post injection mice showed signs of ill health and were humanely killed. Samples were collected from 
bone marrow, spleen and liver. Flow cytometry determined RFP and GFP ratio of leukemia cells after 
propagation in vivo. 
SDS-PAGE and Western Blot 
Proteins of whole cell lysates in Laemmli buffer (32.9 mM Tris-HCl pH 6.8, 13.15% glycerol, 1.05% SDS, 
0.005% bromophenol blue) were separated by SDS-PAGE and transferred onto 
Polyvinylidenedifluoride membranes (Merck Millipore). The following primary antibodies were used: 
LCK (#2984, clone D88), p-SRC (Tyr416) (#6943, clone D49G4), p-LCK (Tyr505) (#2751), p-PLCγ1 
(Tyr783) (#2821), PLCγ1 (#5690, clone D9H10) (all purchased from Cell Signalling), GAPDH (Cat#5G4, 
clone 6C5, Hytest, Finland) and Clathrin. Secondary antibodies were from Dako (CA, USA): Goat Anti-
Mouse IgG HRP (P0447), Goat Anti-Rabbit IgG (P0448). For developing Immobilon Western 
Chemiluminescent HRP Substrate (Millipore) and the ChemiDoc MP Imaging System with Image Lab 
Software (Bio-Rad) has been used. 
RNA extraction and quantitative real-time PCR 
RNA was extracted from 5 x 106 cells using the RNeasy Mini Kit (Qiagen, UK). Briefly, cells were 
collected at 500 x g for 3 mins and lysed in RLT buffer with 1% β-mercaptoethanol. The cell lysates 
were transferred to a QIAshredder column and centrifuged at 8,000 x g for 2mins. The flow-through 
was mixed with 70% Ethanol and moved to the RNeasy mini-spin column. After the centrifugation, the 
flow-through was discarded, and the column was washed twice with RW1 and RPE buffer respectively. 
Finally, the column was dried off by centrifugation at maximum speed for 2 mins. The RNA was 
dissolved in RNase-free water and eluted from the column by centrifugation at 8,000 x g for 2 mins. 
The cDNA was synthesized according to manufacturer’s protocol by RevertAid H Minus First Strand 
cDNA Synthesis Kit (Thermo scientific#1631, Paisley, UK). The primers for qRT-PCR (Supplementary 
Table S3) were ordered from Sigma Aldrich (Dorset, UK). Samples were run on Applied Biosystems ViiA 
7 (ThermoFisher, Paisley, UK). Relative mRNA expression was expressed as 2-DCt. 
Bioinformatics analysis Drug matrix synergy 
The threshold analysis of log Dexamethasone was used to identify the optimum threshold for this 
drug. We have started from the minimum value (-3) and maximum value (7) and added or subtracted 
one unite at the time respectably. Similar method was used to access the optimum threshold of 
Dasatinib. This time for the minimum value (-13) and maximum value of (4). The proportion 
significance of cases within the threshold and synergy was calculated using fisher’s exact test. 
Xenotransplantation experiments 
Mice used in this project were bred and housed in the Newcastle University Comparative Biology 
Centre under specific pathogen-free conditions. A flow hood (FASTER S.r.l, Cornaredo (MI), Italy) was 
used for sterilized manipulations or experiments. All mouse work was approved and followed Home 
Office Project License PPL60/4552 and carried out by researchers with Home Office Personal License 
under the Animal (Scientific Procedures) Act 1986. All mice were humanely killed by a schedule 1 
method when they exhibited endpoints as specified by the license. For example, when tumors reached 
1.5 cm in diameter, if they lost > 10% weight compared to controls for 3 consecutive days or 20% at 
any time, or displayed signs of ill health. 
Mouse Toxicity Studies 
A pilot toxicity study in a small number of NSG mice was carried to explore the maximal tolerant dosing 
of dasatinib in combination with 1 mg/kg dexamethasone. Six healthy mice (three males and three 
females) were dosed daily (Monday to Friday) with one dosing of combined 1 mg/kg dexamethasone 
and dasatinib by intraperitoneal (IP) injection. Mice were examined and weighed daily upon the drug 
administration. The starting dose of dasatinib was 5 mg/kg. Later the dose increased to 10 mg/kg, 
20mg/kg and 35mg/kg for the highest dose. The initial drug was dissolved in DMSO stock and 
subsequently diluted down in water. On the 3rd week of combination of 1 mg/kg dexamethasone and 
35 mg/kg dasatinib, all six mice lost 10-15% of weights indicating that they could not tolerate this dose 
any more. Dosing was stopped and the weights were monitoring continuously for 10 days. Mice gain 
weights gradually afterwards and were back to their original weights. The maximal tolerant dosing for 
NSG mice is 35 mg/kg dasatinib with 1 mg/kg dexamethasone for three weeks.  
Harvesting of Leukemic Cells from Mice  
Spleen samples were homogenized through a cell strainer and bone marrow samples were harvested 
by flushing the lumens with PBS or crushing bones with a pestle and mortar with PBS. 
Histological examination of murine heads 
Murine heads were stripped of soft tissues and decalcified in Hilleman and Lee EDTA solution (5.5% 
EDTA in 10% formalin) for 3 weeks, then trimmed and put in fresh EDTA for 4 days. Samples were 
processed on a Tissue-Tek VIP processor using a routine overnight 17.5 hour cycle. Following paraffin 
wax embedding, 2.5µm sections were cut onto Poly-L-silane coated slides. Sections were then stained 
with Gill’s haematoxylin and Putt’s eosin (both made in house). Quantification of CNS infiltration was 
performed using a Hamamatsu Nanozoomer Digital Pathology slide scanner with digital slide 
management/image analysis software from Slidepath (Dublin). CNS infiltration was evaluated as 
previously described 6, the maximal depth of CNS infiltrates was measured across 5 equally spaced 
brain sections per mouse and then averaged, all treatment allocations were blinded to the investigator 
performing the measurements. 
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Supplementary Figures
Supplementary Figure 1A. Relative gene expression of targets in the shRNA screen. In silico analysis,
using the Cancer Cell Line Encyclopedia (CCLE), of gene expression of LCK, FYN, ZAP70, PTCRA, LAT and
CD3E in a panel of cancer cell lines.
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Supplementary Figure 1B. Relative gene expression of LCK and PTCRA in a panel of cell lines and
PDX samples. LCK and pTCRA expression was determined in various T-ALL cell lines, 697 and REH (B-
lineage ALL cell lines) and TK6 (lymphoblastoid cell line) by real time qPCR. GAPDH served as reference
gene for normalization.
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Supplementary Figure 1C-F. Gradual depletion of shLCK#3 in T-ALL cell lines and PDX LK203 ex vivo. Cells
were lentivirally transduced with the pLKO5-shRNA library and the abundance of shRNAs were determined after 40
days (T-ALL cell lines) and 30 days (PDX LK203) growth ex vivo. (C) Volcano plots representing the change in
shRNA representation over time (slope, x-axis) with negative values representing depletion. The y-axis represents
the significance in enrichment or depletion of shRNA constructs (log10 scale). Each dot represents an individual
shRNA construct. Dots above the blue line have significantly changed (p<0.05). (D) Heatmap depicting relative
representation of shRNA constructs after in vitro culture of 4 T-ALL cell lines (40 days). (E) Change in shRNA
representation (logCPM) over time (days) for NTC (red, green), LCK and ZAP70 (lib 1 blue, lib 2 purple). shRNA
derived from library 1 or 2. (F) Volcano plot representing the magnitude of the fold change (log2) in shRNA
abundance derived from PDX LK203 leukemia cells on the x-axis. Each dot represents an individual shRNA
construct. The y-axis represents the significance in enrichment or depletion of shRNA constructs (log10 scale).
Dots above the blue line are significantly depleted (p<0.05).
shRUNX1/ETO
GSupplementary Figure 1G. LCK protein expression in T-ALL. Western Blot analysis of LCK and p-Y416SRC
protein expression in a panel of cell lines (left) and PDX samples (right). Comparative expression of
housekeepers GAPDH and Clathrin is shown.
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Supplementary Figure 2. Competitive assays underline a critical role for LCK in T-ALL cell proliferation.
(A) T-ALL cell line CUTLL1 was transduced with GFP expressing shLCK (blue), shZAP70 (purple), shPTCRA
(red) or shNTC (black; RUNX1/ETO, FLG, NTC) expressing constructs. The cells were seeded in a 1:1 ratio with
non-transduced parental cells in vitro. Cells were cultured and analyzed repetitively for the presence of GFP+
cells over a time period of 40 days. A relative GFP expression of 1 denotes a mixture of 50% GFP+ cells with
50% parental cells (ratio 1:1). A value of 0.5 means GFP+ cells represent 25% of total cells (ratio 1:4). Three
separate shRNAs (#1,2,3) were used to target LCK, PTCRA and ZAP70. The knockdown efficiency at mRNA
level is indicated in black bars on the right side of each proliferation plot. (B) CUTLL1 and and MOLT4 cells were
transduced with GFP expressing shFYN (pink) or shNTC (black) constructs and seeded in a 1:1 ratio with non-
transduced parental cells in vitro. Cells were cultured and analyzed repetitively for the presence of GFP+ cells
over a time period of 40 days. The knockdown efficiency at mRNA level is indicated in black bars on the right
side of each proliferation plot. (C) MOLT4 cells were lentivirally transduced with shNTC (non-targeting control),
shLCK#3 (blue), shPTCRA#1 (red), or shZAP70#1 (purple) expression constructs and seeded in a 1:1 ratio with
non-transduced parental cells in vitro. Cells were cultured and analyzed repetitively by flow cytometry for the
presence of GFP+ cells over a time period of 40 days.
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Supplementary Figure 3. Targeted shRNA screen identifies critical role for LCK in T-ALL progression in
immunocompromised NSG mice. (A) Schematic representation of the in vivo targeted shRNA screen. (B)
Volcano plot representing the magnitude of the fold change (log2) in shRNA abundance in PDX L963 bone
marrow on the x-axis. shLCK#3 (red dot) represents the shRNA construct with most significant depletion in bone
marrow. Bar plot of the normalized shLCK#1 sequencing reads (log2) in leukemic cells derived from the bone
marrow (orange) or spleen (blue) of 6 individual mice (M1-6), relative to the frequency of these reads before
transplantation (green, base line B1-3). (C) Flow cytometric analysis of representation of shNTC (red fluorescent
protein, RFP) or shLCK#3 (GFP) constructs in MOLT4 in vivo competitive outgrowth assay. MOLT4 cells were
derived from splenic tissue.
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Supplementary Figure 4. LCK knockdown results in cell cycle
arrest. (A) Cell cycle status was determined by flow cytometry using
Hoechst 33342 in Jurkat and MOLT4 cell lines. (B) Relative S phase
ratio in PDX L963 after transduction with shLCK#3 versus shNTC. (C)
PDX LK203 and L963 cells were electroporated with siRNA directed
against LCK or NTC (Ctrl). Phosflow analysis after 8 days identified
reduction in p-Y416SRC and total LCK, leading to significant cell cycle
arrest in LK203 (**p=0.004, n=3). (E) Flow cytometric analysis of T-ALL
cells stained with PE-Annexin V/7-AAD after knockdown with shNTC or
shLCK#3. Annexin V positivity, as indicator of early apoptosis, is
indicated on the y-axis.
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Supplementary Figure 5. DAS inhibits LCK function and
causes cell cycle arrest. (A-D) Indicated T-ALL cell lines (A,
B) or PDX T-ALL (C-D) were treated with vehicle control or
DAS (2 µM for cell lines, 1 µM for PDXs) for 24 h.
Phosphorylation of total LCK, p-Y416SRC, p-Y505LCK, total
PLCγ1, p-Y783PLCγ1, total ZAP70 and p-Y493ZAP70 was
assessed in Jurkat or CUTLL1 cells (A) and in PDX L970,
L907, LK080 and L809 (C) by Western Blot analysis. (B and D)
Cell cycle was analysed after Hoechst staining and flow
cytometric assessment in various T-ALL cell lines (B) and PDX
LK080 (**p=0.0049, n=3) (D). (E) The in vitro sensitivity of a
panel of PDX samples to DAS (GI50) was correlated with theratio of p-Y416SRC / total LCK as determined by Phosflow.
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Supplementary Figure 6. DEX and DAS act synergistically to induce cell death in T-ALL. (A) Cell viability of
parental CUTLL1 cells transduced with (mock), shNTC, shLCK#1 or shLCK#3 upon treatment with increasing DEX
concentrations (0-1699 nM). (B-D) Drug matrix analyses with titration of DEX (0-600 nM) and DAS (0.08-50 µM)
for 72 h was performed in 10 T-ALL cell lines. (B, left) Cell viability of CUTLL1 with and without DAS (black line, no
DAS; blue line, 0.37 µM; red line, 3.33 µM) in combination with increasing concentrations of DEX (0-600 nM) as
derived from the drug matrix. (B, Right) Combenefit analysis of drug matrix demonstrates drug synergy in CUTLL1
cells at clinically relevant drug concentrations. (C) Combenefit analysis of drug matrix demonstrates varying levels
of drug synergy in T-ALL cell lines. The brown shaded matrices reflect the percentage of viable cell after drug
treatment relative to the percentage of viable cells under control conditions. (D) Bioinformatic analysis of all 10 T-
ALL cell lines revealed a statistically significant enrichment of drug synergy at clinically relevant concentrations
(shaded area). This synergy was observed at 8-110 nM of DEX and 0.223-4.5 µM of DAS. Each circle represents
one measurement in the drug matrices of 10 cell lines. Circle color represents cell viability. Circle size represents
level of synergy calculated.
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Supplementary Figure 6. (E) Combenefit analysis of drug matrices demonstrates varying levels of drug synergy
in T-ALL PDX samples. The brown shaded matrices reflect cell viability (%) after drug treatment relative to the cell
viability determined under control conditions.
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Supplementary Figure 6. (F) Bioinformatic analysis of drug matrices/Combenefit analyses of all PDX samples
revealed a statistically significant enrichment of drug synergy at clinically relevant concentrations (shaded area).
This synergy was observed at 8-110 nM of DEX and 0.223-4.5 µM of DAS. Circle color represents cell viability.
Circle size represents level of synergy calculated. (G) Real time qPCR analysis of GILZ mRNA expression in the cell
lines CCRF-CEM, CUTLL1, Jurkat, SUPT1, MOLT16, MOLT4, PDX L970, L809, LK080, L907 and LK203 after
exposure to control (Ctrl) conditions, DAS (2 µM for cell lines and 1 µM for PDXs), DEX (100 nM) or DAS+DEX
combination treatment at the same concentrations for 24 h. GILZ mRNA expression was normalized to GAPDH
mRNA expression. Red shading of boxes represent GILZ expression relative to control condition.
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GSupplementary Figure 7. DEX + DAS synergize to impair leukemia engraftment in a phase II-like murine trial.
(A) Summary of final human CD45+ engraftment (%) in peripheral blood (left), spleen (middle) and bone marrow
(right) of mice treated with Ctrl (black), DAS (blue), DEX (green) or DEX+DAS (red). Paired student t-test was used.
Peripheral blood: Ctrl vs DEX+DAS ***p<0.00001, DAS vs DEX+DAS **p=0.00126, DEX vs DEX+DAS
***p=0.00032. Spleen: Ctrl vs DEX+DAS *p=0.01068, DAS vs DEX+DAS **p=0.004259, DEX vs DEX+DAS
*p=0.01425. Bone marrow: Ctrl vs DEX+DAS ***p=0.0003, DAS vs DEX+DAS **p=0.0056, DEX vs DEX+DAS
*p=0.01579. (B) Average depth of CNS infiltrate across 5 coronal sections per mouse analyzed by paired t-test,
significance level *p<0.05. Table. Individual values for average depth of infiltrate across 5 sections measured in µm
for each patient sample in the phase II-like trial. (C) Summary of spleen weight in mice treated with Ctrl (black), DAS
(blue), DEX (green) or DEX+DAS (red). Paired student t-test was used. Ctrl vs DEX+DAS **p=0.002996, DAS vs
DEX+DAS **p=0.006699, DEX vs DEX+DAS ***p<0.00001. (D) Spleen size and weight in mice derived from 5 PDX
samples treated with Ctrl, DAS, DEX or DEX+DAS. (E) Summary of final human CD7+ or CD45+ engraftment (%) in
liver of mice treated with Ctrl (black), DAS (blue), DEX (green) or DEX+DAS (red). Paired student t-test was used.
Top: Ctrl vs DEX+DAS **p=0.001248, DAS vs DEX+DAS *p=0.01155, DEX vs DEX+DAS *p=0.03188. Bottom: Ctrl
vs DEX+DAS **p=0.002323, DAS vs DEX+DAS **p=0.00503, DEX vs DEX+DAS *p=0.02264. (F) Western blotting
of total and phosphorylated LCK (p-Y416SRC) protein levels of flow sorted hCD45+ cell lysates derived from the
spleens of 4 mice injected with PDX L809 under 4 different treatment arms (Ctrl, DAS, DEX or DEX+DAS) relative to
the housekeepers GAPDH and Clathrin (top). Western blotting of total and phosphorylated LCK protein levels of
whole cell lysates of PDX L809 cells (97% purity) treated in vitro for 24 hours with Ctrl, DAS (1 µM), DEX (100 nM)
or DEX+DAS, relative to the housekeepers GAPDH and Clathrin. (G) Engraftment of hCD45+ cells (%) was
determined weekly in peripheral blood derived from mice injected with PDX samples. Engraftment levels are shown
starting from day of injection (day 0) in mice receiving control vehicle (Ctrl, black), DAS (blue), DEX (green) or
DEX+DAS (red). The vertical dotted lines indicate the treatment window.
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Supplementary Figure 1A. Relative gene expression of targets in the shRNA 
screen. In silico analysis, using the Cancer Cell Line Encyclopedia (CCLE), of gene 
expression of LCK, FYN, ZAP70, PTCRA, LAT and CD3E in a panel of cancer cell 
lines. 
Supplementary Figure 1B. Relative gene expression of LCK and PTCRA in a 
panel of cell lines and PDX samples. LCK and pTCRA expression was determined 
in various T-ALL cell lines, 697 and REH (B-lineage ALL cell lines) and TK6 
(lymphoblastoid cell line) by real time qPCR. GAPDH served as reference gene for 
normalization. 
Supplementary Figure 1C-F. Gradual depletion of shLCK#3 in T-ALL cell lines 
and PDX LK203 ex vivo. Cells were lentivirally transduced with the pLKO5-shRNA 
library and the abundance of shRNAs were determined after 40 days (T-ALL cell lines) 
and 30 days (PDX LK203) growth ex vivo (C) Volcano plots representing the change 
in shRNA representation over time (slope, x-axis) with negative values representing 
depletion. The y-axis represents the significance in enrichment or depletion of shRNA 
constructs (log10 scale). Each dot represents an individual shRNA construct. Dots 
above the blue line have significantly changed (p<0.05). (D) Heatmap depicting relative 
representation of shRNA constructs after in vitro culture of 4 T-ALL cell lines (40 days). 
(E) Change in shRNA representation (logCPM) over time (days) for NTC (red, green), 
LCK and ZAP70 (lib 1 blue, lib 2 purple). shRNA derived from library 1 or 2. (F) Volcano 
plot representing the magnitude of the fold change (log2) in shRNA abundance derived 
from PDX LK203 leukemia cells on the x-axis. Each dot represents an individual 
shRNA construct. The y-axis represents the significance in enrichment or depletion of 
shRNA constructs (log10 scale). Dots above the blue line are significantly depleted 
(p<0.05). 
Supplementary Figure 1G. LCK protein expression in T-ALL. Western Blot 
analysis of LCK and p-Y416SRC protein expression in a panel of cell lines (left) and 
PDX samples (right). Comparative expression of housekeepers GAPDH and Clathrin 
is shown. 
Supplementary Figure 2. Competitive assays underline a critical role for LCK in 
T-ALL cell proliferation. (A) T-ALL cell line CUTLL1 was transduced with GFP 
expressing shLCK (blue), shZAP70 (purple),  shPTCRA (red) or shNTC (black; 
RUNX1/ETO, FLG, NTC) expressing constructs. The cells were seeded in a 1:1 ratio 
with non-transduced parental cells in vitro. Cells were cultured and analyzed 
repetitively for the presence of GFP+ cells over a time period of 40 days. A relative 
GFP expression of 1 denotes a mixture of 50% GFP+ cells with 50% parental cells 
(ratio 1:1). A value of 0.5 means GFP+ cells represent 25% of total cells (ratio 1:4). 
Three separate shRNAs (#1,2,3) were used to target LCK, PTCRA and ZAP70. The 
knockdown efficiency at mRNA level is indicated in black bars on the right side of each 
proliferation plot. (B) CUTLL1 and and MOLT4 cells were transduced with GFP 
expressing shFYN (pink) or shNTC (black) constructs and seeded in a 1:1 ratio with 
non-transduced parental cells in vitro. Cells were cultured and analyzed repetitively for 
the presence of GFP+ cells over a time period of 40 days. The knockdown efficiency 
at mRNA level is indicated in black bars on the right side of each proliferation plot. (C) 
MOLT4 cells were lentivirally transduced with shNTC (non-targeting control), shLCK#3 
(blue), shPTCRA#1 (red), or shZAP70#1 (purple) expression constructs and seeded 
in a 1:1 ratio with non-transduced parental cells in vitro. Cells were cultured and 
analyzed repetitively by flow cytometry for the presence of GFP+ cells over a time 
period of 40 days. 
 
Supplementary Figure 3. Targeted shRNA screen identifies critical role for LCK 
in T-ALL progression in immunocompromised NSG mice.  (A) Schematic 
representation of the in vivo targeted shRNA screen. (B) Volcano plot representing the 
magnitude of the fold change (log2) in shRNA abundance in PDX L963 bone marrow 
on the x-axis. shLCK#3 (red dot) represents the shRNA construct with most significant 
depletion in bone marrow. Bar plot of the normalized shLCK#1 sequencing reads (log2) 
in leukemic cells derived from the bone marrow (orange) or spleen (blue) of 6 individual 
mice (M1-6), relative to the frequency of these reads before transplantation (green, 
base line B1-3). (C) Flow cytometric analysis of representation of shNTC (red 
fluorescent protein, RFP) or shLCK#3 (GFP) constructs in MOLT4 in vivo competitive 
outgrowth assay. MOLT4 cells were derived from splenic tissue. 
Supplementary Figure 4. LCK knockdown results in cell cycle arrest. (A) Cell 
cycle status was determined by flow cytometry using Hoechst 33342 in Jurkat and 
MOLT4 cell lines. (B) Relative S phase ratio in PDX L963 after transduction with 
shLCK#3 versus shNTC. (C) PDX LK203 and L963 cells were electroporated with 
siRNA directed against LCK or NTC (Ctrl). Phosflow analysis after 8 days identified 
reduction in p-Y416SRC and total LCK, leading to significant cell cycle arrest in LK203 
(**p=0.004, n=3). (E) Flow cytometric analysis of T-ALL cells stained with PE-Annexin 
V/7-AAD after knockdown with shNTC or shLCK#3. Annexin V positivity, as indicator 
of early apoptosis, is indicated on the y-axis.  
Supplementary Figure 5. DAS inhibits LCK function and causes cell cycle arrest. 
(A-D) Indicated T-ALL cell lines (A, B) or PDX T-ALL (C-D) were treated with vehicle 
control or DAS (2 µM for cell lines, 1 µM for PDXs) for 24 h. Phosphorylation of total 
LCK, p-Y416SRC, p-Y505LCK, total PLCγ1, p-Y783PLCγ1, total ZAP70 and p-Y493ZAP70 
was assessed in Jurkat or CUTLL1 cells (A) and in PDX L970, L907, LK080 and L809 
(C) by Western Blot analysis. (B and D) Cell cycle was analysed after Hoechst staining 
and flow cytometric assessment in various T-ALL cell lines (B) and PDX LK080 
(**p=0.0049, n=3) (D). (E) The in vitro sensitivity of a panel of PDX samples to DAS 
(GI50) was correlated with the ratio of p-Y416SRC / total LCK as determined by 
Phosflow. 
Supplementary Figure 6. DEX and DAS act synergistically to induce cell death in 
T-ALL. (A) Cell viability of parental CUTLL1 cells transduced with (mock), shNTC, 
shLCK#1 or shLCK#3 upon treatment with increasing DEX concentrations (0-1699 
nM). (B-F) Drug matrix analyses with titration of DEX (0-600 nM) and DAS (0.08-50 
µM) for 72 h was performed in 10 T-ALL cell lines.  (B, left) Cell viability of CUTLL1 
with and without DAS (black line, no DAS; blue line, 0.37 µM; red line, 3.33 µM) in 
combination with increasing concentrations of DEX (0-600 nM) as derived from the 
drug matrix. (B, Right) Combenefit analysis of drug matrix demonstrates drug synergy 
in CUTLL1 cells at clinically relevant drug concentrations. (C) Combenefit analysis of 
drug matrix demonstrates varying levels of drug synergy in T-ALL cell lines. The brown 
shaded matrices reflect the percentage of viable cell after drug treatment relative to 
the percentage of viable cells under control conditions. (D) Bioinformatic analysis of all 
10 T-ALL cell lines revealed a statistically significant enrichment of drug synergy at 
clinically relevant concentrations (shaded area). This synergy was observed at 8-110 
nM of DEX and 0.223-4.5 µM of DAS. Each circle represents one measurement in the 
drug matrices of 10 cell lines. Circle color represents cell viability. Circle size 
represents level of synergy calculated.   
Supplementary Figure 6. (E) Combenefit analysis of drug matrices demonstrates 
varying levels of drug synergy in T-ALL PDX samples. The brown shaded matrices 
reflect cell viability (%) after drug treatment relative to the cell viability determined under 
control conditions. 
Supplementary Figure 6. (F) Bioinformatic analysis of drug matrices/Combenefit 
analyses of all PDX samples revealed a statistically significant enrichment of drug 
synergy at clinically relevant concentrations (shaded area). This synergy was observed 
at 8-110 nM of DEX and 0.223-4.5 µM of DAS. Circle color represents cell viability. 
Circle size represents level of synergy calculated. (G) Real time qPCR analysis of GILZ 
mRNA expression in the cell lines CCRF-CEM, CUTLL1, Jurkat, SUPT1, MOLT16, 
MOLT4, PDX L970, L809, LK080, L907 and LK203 after exposure to control (Ctrl) 
conditions, DAS (2 µM for cell lines and 1 µM for PDXs), DEX (100 nM) or DAS+DEX 
combination treatment at the same concentrations for 24 h. GILZ mRNA expression 
was normalized to GAPDH mRNA expression. Red shading of boxes represent GILZ 
expression relative to control condition.  
Supplementary Figure 7. DEX + DAS synergize to impair leukemia engraftment 
in a phase II-like murine trial. (A) Summary of final human CD45+ engraftment (%) 
in peripheral blood (left), spleen (middle) and bone marrow (right) of mice treated with 
Ctrl (black), DAS (blue), DEX (green) or DEX+DAS (red). Paired student t-test was 
used. Peripheral blood: Ctrl vs DEX+DAS ***p<0.00001, DAS vs DEX+DAS 
**p=0.00126, DEX vs DEX+DAS ***p=0.00032. Spleen: Ctrl vs DEX+DAS *p=0.01068, 
DAS vs DEX+DAS **p=0.004259, DEX vs DEX+DAS *p=0.01425. Bone marrow: Ctrl 
vs DEX+DAS ***p=0.0003, DAS vs DEX+DAS **p=0.0056, DEX vs DEX+DAS 
*p=0.01579. (B) Average depth of CNS infiltrate across 5 coronal sections per mouse 
analyzed by paired t-test, significance level *p<0.05. Table. Individual values for 
average depth of infiltrate across 5 sections measured in µm for each patient sample 
in the phase II-like trial. (C) Summary of spleen weight in mice treated with Ctrl (black), 
DAS (blue), DEX (green) or DEX+DAS (red). Paired student t-test was used. Ctrl vs 
DEX+DAS **p=0.002996, DAS vs DEX+DAS **p=0.006699, DEX vs DEX+DAS 
***p<0.00001.. (D) Spleen size and weight in mice derived from 5 PDX samples treated 
with Ctrl, DAS, DEX or DEX+DAS. (E) Summary of final human CD7+ or CD45+ 
engraftment (%) in liver of mice treated with Ctrl (black), DAS (blue), DEX (green) or 
DEX+DAS (red). Paired student t-test was used. Top: Ctrl vs DEX+DAS **p=0.001248, 
DAS vs DEX+DAS *p=0.01155, DEX vs DEX+DAS *p=0.03188. Bottom: Ctrl vs 
DEX+DAS **p=0.002323, DAS vs DEX+DAS **p=0.00503, DEX vs DEX+DAS 
*p=0.02264. (F) Western blotting of total and phosphorylated LCK (p-Y416SRC) protein 
levels of flow sorted hCD45+ cell lysates derived from the spleens of 4 mice injected 
with PDX L809 under 4 different treatment arms (Ctrl, DAS, DEX or DEX+DAS) relative 
to the housekeepers GAPDH and Clathrin (top). Western blotting of total and 
phosphorylated LCK protein levels of whole cell lysates of PDX L809 cells (97% purity) 
treated in vitro for 24 hours with Ctrl, DAS (1 µM), DEX (100 nM) or DEX+DAS, relative 
to the housekeepers GAPDH and Clathrin. (G) Engraftment of hCD45+ cells (%) was 
determined weekly in peripheral blood derived from mice injected with PDX samples. 
Engraftment levels are shown starting from day of injection (day 0) in mice receiving 
control vehicle (Ctrl, black), DAS (blue), DEX (green) or DEX+DAS (red). The vertical 
dotted lines indicate the treatment window. 
Gene Oligo Sequences
1F shFYN#1 AGCGACCGATTGATAGAAGACAATGATAGTGAAGCCACAGATGTATCATTGTCTTCTATCAATCGGG
1R GGCACCCGATTGATAGAAGACAATGATACATCTGTGGCTTCACTATCATTGTCTTCTATCAATCGGT
2F sh#FYN2 AGCGAAAGACAATGAGTACACAGCAATAGTGAAGCCACAGATGTATTGCTGTGTACTCATTGTCTTC
2R GGCAGAAGACAATGAGTACACAGCAATACATCTGTGGCTTCACTATTGCTGTGTACTCATTGTCTTT
3F shFYN#3 AGCGAATAGAGATCTGCGATCAGCAATAGTGAAGCCACAGATGTATTGCTGATCGCAGATCTCTATG
3R GGCACATAGAGATCTGCGATCAGCAATACATCTGTGGCTTCACTATTGCTGATCGCAGATCTCTATT
4F shLCK#1 AGCGACGGAATTATATTCATCGTGACTAGTGAAGCCACAGATGTAGTCACGATGAATATAATTCCGC
4R GGCAGCGGAATTATATTCATCGTGACTACATCTGTGGCTTCACTAGTCACGATGAATATAATTCCGT
5F shLCK#2 AGCGACACATGTCTTGTACATGTGTATAGTGAAGCCACAGATGTATACACATGTACAAGACATGTGC
5R GGCAGCACATGTCTTGTACATGTGTATACATCTGTGGCTTCACTATACACATGTACAAGACATGTGT
6F shLCK#3 AGCGACCCATCTACATCATCACTGAATAGTGAAGCCACAGATGTATTCAGTGATGATGTAGATGGGC
6R GGCAGCCCATCTACATCATCACTGAATACATCTGTGGCTTCACTATTCAGTGATGATGTAGATGGGT
7F shPTCRA#1 AGCGCGCAGATGACTGAGAACATTAATAGTGAAGCCACAGATGTATTAATGTTCTCAGTCATCTGCT
7R GGCAAGCAGATGACTGAGAACATTAATACATCTGTGGCTTCACTATTAATGTTCTCAGTCATCTGCG
8F shPTCRA#2 AGCGACAGCACAGGCCTGGTGCTCAATAGTGAAGCCACAGATGTATTGAGCACCAGGCCTGTGCTGG
8R GGCACCAGCACAGGCCTGGTGCTCAATACATCTGTGGCTTCACTATTGAGCACCAGGCCTGTGCTGT
9F shPTCRA#3 AGCGCAGGGTCTTACCTCAGCAGTTATAGTGAAGCCACAGATGTATAACTGCTGAGGTAAGACCCTT
9R GGCAAAGGGTCTTACCTCAGCAGTTATACATCTGTGGCTTCACTATAACTGCTGAGGTAAGACCCTG
10F shZAP70#1 AGCGCGGCGTAGATCACCAGAATAAATAGTGAAGCCACAGATGTATTTATTCTGGTGATCTACGCCT
10R GGCAAGGCGTAGATCACCAGAATAAATACATCTGTGGCTTCACTATTTATTCTGGTGATCTACGCCG
11F shZAP70#2 AGCGAGCCCTGTCCCTCATCTATGGGTAGTGAAGCCACAGATGTACCCATAGATGAGGGACAGGGCG
11R GGCACGCCCTGTCCCTCATCTATGGGTACATCTGTGGCTTCACTACCCATAGATGAGGGACAGGGCT
12F shZAP70#3 AGCGCCGGCCAGAAGCCCTACAAGAATAGTGAAGCCACAGATGTATTCTTGTAGGGCTTCTGGCCGT
12R GGCAACGGCCAGAAGCCCTACAAGAATACATCTGTGGCTTCACTATTCTTGTAGGGCTTCTGGCCGG
13F shLAT#1 AGCGCCCATGGAGTCCATTGATGATTTAGTGAAGCCACAGATGTAAATCATCAATGGACTCCATGGA
13R GGCATCCATGGAGTCCATTGATGATTTACATCTGTGGCTTCACTAAATCATCAATGGACTCCATGGG
14F shLAT#2 AGCGCCAGTGTGGCGAGCTACGAGAATAGTGAAGCCACAGATGTATTCTCGTAGCTCGCCACACTGT
14R GGCAACAGTGTGGCGAGCTACGAGAATACATCTGTGGCTTCACTATTCTCGTAGCTCGCCACACTGG
15F shLAT#3 AGCGCCCTCAGATAGTTTGTATCCAATAGTGAAGCCACAGATGTATTGGATACAAACTATCTGAGGA
15R GGCATCCTCAGATAGTTTGTATCCAATACATCTGTGGCTTCACTATTGGATACAAACTATCTGAGGG
16F shCD3E#1 AGCGCACCAGAAGATGCGAACTTTTATAGTGAAGCCACAGATGTATAAAAGTTCGCATCTTCTGGTT
16R GGCAAACCAGAAGATGCGAACTTTTATACATCTGTGGCTTCACTATAAAAGTTCGCATCTTCTGGTG
17F shCD3E#2 AGCGAGGGCAAGATGGTAATGAAGAATAGTGAAGCCACAGATGTATTCTTCATTACCATCTTGCCCC
17R GGCAGGGGCAAGATGGTAATGAAGAATACATCTGTGGCTTCACTATTCTTCATTACCATCTTGCCCT
18F shCD3E#3 AGCGACCCTCTTGCCAGGATATTTATTAGTGAAGCCACAGATGTAATAAATATCCTGGCAAGAGGGC
18R GGCAGCCCTCTTGCCAGGATATTTATTACATCTGTGGCTTCACTAATAAATATCCTGGCAAGAGGGT
19F shRPL9#1 AGCGCGCCCAGAAAGATGAATTAATCTAGTGAAGCCACAGATGTAGATTAATTCATCTTTCTGGGCT
19R GGCAAGCCCAGAAAGATGAATTAATCTACATCTGTGGCTTCACTAGATTAATTCATCTTTCTGGGCG
20F shRPL9#2 AGCGAACATTGAGCTTGTTTCAAATTTAGTGAAGCCACAGATGTAAATTTGAAACAAGCTCAATGTC
20R GGCAGACATTGAGCTTGTTTCAAATTTACATCTGTGGCTTCACTAAATTTGAAACAAGCTCAATGTT
21F shRPS29#1 AGCGCTCCGTCAGTACGCGAAGGATATAGTGAAGCCACAGATGTATATCCTTCGCGTACTGACGGAA
21R GGCATTCCGTCAGTACGCGAAGGATATACATCTGTGGCTTCACTATATCCTTCGCGTACTGACGGAG
22F shRPS29#2 AGCGACGGCACGGTCTGATCCGGAAATAGTGAAGCCACAGATGTATTTCCGGATCAGACCGTGCCGG
22R GGCACCGGCACGGTCTGATCCGGAAATACATCTGTGGCTTCACTATTTCCGGATCAGACCGTGCCGT
23F shCD19#1 AGCGCGCTCAAGACGCTGGAAAGTATTAGTGAAGCCACAGATGTAATACTTTCCAGCGTCTTGAGCT
23R GGCAAGCTCAAGACGCTGGAAAGTATTACATCTGTGGCTTCACTAATACTTTCCAGCGTCTTGAGCG
24F shCD19#2 AGCGCCCCCACCAGGAGATTCTTCAATAGTGAAGCCACAGATGTATTGAAGAATCTCCTGGTGGGGT
24R GGCAACCCCACCAGGAGATTCTTCAATACATCTGTGGCTTCACTATTGAAGAATCTCCTGGTGGGGG
25F shTRPM7#1 AGCGCGCCCTGACGGTAGATACATTATAGTGAAGCCACAGATGTATAATGTATCTACCGTCAGGGCT
25R GGCAAGCCCTGACGGTAGATACATTATACATCTGTGGCTTCACTATAATGTATCTACCGTCAGGGCG
26F shTRPM7#2 AGCGCGCTGCAGATCTGCTAGCGTATTAGTGAAGCCACAGATGTAATACGCTAGCAGATCTGCAGCT
26R GGCAAGCTGCAGATCTGCTAGCGTATTACATCTGTGGCTTCACTAATACGCTAGCAGATCTGCAGCG
27F shKLHL7 AGCGCGCAGTTGGCTCTATAGTTTATTAGTGAAGCCACAGATGTAATAAACTATAGAGCCAACTGCT
27R GGCAAGCAGTTGGCTCTATAGTTTATTACATCTGTGGCTTCACTAATAAACTATAGAGCCAACTGCG
28F shDDB2 AGCGAGGAGATATCATGCTCTGGAATTAGTGAAGCCACAGATGTAATTCCAGAGCATGATATCTCCC
28R GGCAGGGAGATATCATGCTCTGGAATTACATCTGTGGCTTCACTAATTCCAGAGCATGATATCTCCT
29F shSESN2 AGCGCGGAGGGAGTATTAGATTATAATAGTGAAGCCACAGATGTATTATAATCTAATACTCCCTCCT
29R GGCAAGGAGGGAGTATTAGATTATAATACATCTGTGGCTTCACTATTATAATCTAATACTCCCTCCG
30F shERGIC3 AGCGACCTTCAAGAACCCAGATACTATAGTGAAGCCACAGATGTATAGTATCTGGGTTCTTGAAGGC
30R GGCAGCCTTCAAGAACCCAGATACTATACATCTGTGGCTTCACTATAGTATCTGGGTTCTTGAAGGT
31F shFLG AGCGCGGATATAGACCACAACAAGAATAGTGAAGCCACAGATGTATTCTTGTTGTGGTCTATATCCA
31R GGCATGGATATAGACCACAACAAGAATACATCTGTGGCTTCACTATTCTTGTTGTGGTCTATATCCG
32F shRUNX1/ETO AGCGAAACCTCGAAATCGTACTGAGATAGTGAAGCCACAGATGTATCTCAGTACGATTTCGAGGTTC
32R GGCAGAACCTCGAAATCGTACTGAGATACATCTGTGGCTTCACTATCTCAGTACGATTTCGAGGTTT
33F shPTEN#1 AGCGAAGGCGCTATGTGTATTATTATTAGTGAAGCCACAGATGTAATAATAATACACATAGCGCCTC
33R GGCAGAGGCGCTATGTGTATTATTATTACATCTGTGGCTTCACTAATAATAATACACATAGCGCCTT
34F shPTEN#2 AGCGCCACGACGGGAAGACAAGTTCATAGTGAAGCCACAGATGTATGAACTTGTCTTCCCGTCGTGT
34R GGCAACACGACGGGAAGACAAGTTCATACATCTGTGGCTTCACTATGAACTTGTCTTCCCGTCGTGG
35F shPTEN#3 AGCGACCAGCTAAAGGTGAAGATATATAGTGAAGCCACAGATGTATATATCTTCACCTTTAGCTGGC
35R GGCAGCCAGCTAAAGGTGAAGATATATACATCTGTGGCTTCACTATATATCTTCACCTTTAGCTGGT
36F shNTC AGCGATCTCGCTTGGGCGAGAGTAAGTAGTGAAGCCACAGATGTACTTACTCTCGCCCAAGCGAGAG
36R GGCACTCTCGCTTGGGCGAGAGTAAGTACATCTGTGGCTTCACTACTTACTCTCGCCCAAGCGAGAT
Supplementary Table 1. Sequences of shRNAs used in targeted screen.
shRNA gene slope logCPM LR PValue FDR
shCD19#1 CD19 -0.01426 14.71381 0.229565 0.631846 0.787689
shCD19#2 CD19 0.01455 14.51295 0.233252 0.629123 0.787689
shCD3e#1 CD3e -0.00759 14.72741 0.066942 0.795843 0.842657
shCD3e#2 CD3e -0.01372 14.76283 0.225394 0.63496 0.787689
shCD3e#3 CD3e 0.017933 14.88124 0.403658 0.525206 0.787689
shDDB2 DDB2 0.00466 15.3542 0.028696 0.865483 0.865483
shERGIC3 ERGIC3 -0.01392 14.61057 0.229422 0.631952 0.787689
shFLG FLG -0.01381 15.7347 0.258837 0.61092 0.787689
shFYN#1 FYN -0.03403 14.6642 1.363196 0.242984 0.460391
shFYN#2 FYN -0.03946 14.81744 1.948541 0.162744 0.344635
shFYN#3 FYN 0.021791 14.52647 0.547283 0.45943 0.787594
shKLHL7 KLHL7 0.014446 14.82185 0.258797 0.610948 0.787689
shLAT#1 LAT 0.012082 14.28583 0.142321 0.705985 0.787689
shLAT#2 LAT 0.049563 14.24421 2.267049 0.132151 0.29734
shLAT#3 LAT 0.011454 14.41083 0.137908 0.71037 0.787689
shLCK#1 LCK -0.05504 14.65581 3.562372 0.059103 0.173345
shLCK#2 LCK -0.01924 15.03996 0.410081 0.521928 0.787689
shLCK#3 LCK -0.35675 14.29463 132.3253 1.27E-30 4.57E-29
shNTC NTC 0.026824 14.92501 0.916581 0.338374 0.609074
shPTCRA#1 PTCRA 0.144236 14.12509 14.74569 0.000123 0.000554
shPTCRA#2 PTCRA 0.04774 14.35548 2.492345 0.114401 0.286763
shPTCRA#3 PTCRA -0.00638 14.61162 0.044858 0.832265 0.856044
shPTEN#1 PTEN 0.233804 15.29035 71.80669 2.37E-17 2.14E-16
shPTEN#2 PTEN 0.10558 14.9605 12.22175 0.000472 0.001889
shPTEN#3 PTEN 0.270945 14.94674 89.43219 3.17E-21 5.71E-20
shRPL9#1 RPL9 -0.03939 14.58448 1.841226 0.174807 0.349615
shRPL9#2 RPL9 -0.06889 15.13805 5.806092 0.015971 0.052268
shRPS29#1 RPS29 -0.04414 14.94927 2.424066 0.119484 0.286763
shRPS29#2 RPS29 0.287987 13.31127 41.1585 1.40E-10 1.01E-09
shRUNX1/ETORUNX1/ETO 0.009921 15.20024 0.126539 0.722048 0.787689
shSESN2 SESN2 0.080821 14.62455 7.360335 0.006668 0.024004
shTRPM7#1 TRPM7 -0.13288 14.8739 18.39057 1.80E-05 9.25E-05
shTRPM7#2 TRPM7 -0.24783 14.66783 74.99375 4.72E-18 5.67E-17
shZAP70#1 ZAP70 -0.14383 14.17178 19.57463 9.67E-06 5.80E-05
shZAP70#2 ZAP70 -0.05783 15.04069 3.467211 0.062597 0.173345
shZAP70#3 ZAP70 0.01156 14.50116 0.149549 0.698967 0.787689
Slope = regression slope
LogCPM = log counts per million
LR = linear regression
Pvalue = calculated probability
FDR = false discovery rate
Supplementary Table 2. Change in shRNA count over time in CUTLL1.
shRNA gene slope logCPM LR PValue FDR
shCD19#1 CD19 -0.02494 14.61324 0.360766 0.548081 0.563741
shCD19#2 CD19 0.322201 14.00891 15.24878 9.42E-05 0.000261
shCD3e#1 CD3e 0.074454 14.68732 0.737249 0.390543 0.438663
shCD3e#2 CD3e -0.02839 14.99087 0.530497 0.466398 0.493833
shCD3e#3 CD3e 0.110724 14.81066 5.815661 0.015884 0.028591
shDDB2 DDB2 -0.07671 15.54087 4.91949 0.026555 0.043454
shERGIC3 ERGIC3 0.149835 14.66639 8.681668 0.003214 0.00609
shFLG FLG -0.03314 15.809 0.840896 0.359141 0.417067
shFYN#1 FYN -0.1067 14.72682 8.761949 0.003076 0.00609
shFYN#2 FYN -0.1498 15.14792 10.77279 0.00103 0.002181
shFYN#3 FYN 0.052444 14.53822 1.91671 0.16622 0.213711
shKLHL7 KLHL7 0.094138 14.73021 3.918114 0.047768 0.068787
shLAT#1 LAT -0.07844 14.33617 4.559337 0.03274 0.04911
shLAT#2 LAT 0.448203 13.41074 82.51448 1.05E-19 9.44E-19
shLAT#3 LAT -0.08526 14.49881 3.410346 0.064789 0.089708
shLCK#1 LCK -0.12064 14.80174 10.8718 0.000976 0.002181
shLCK#2 LCK -0.16964 15.37185 20.91965 4.79E-06 1.57E-05
shLCK#3 LCK -0.30854 14.80821 71.77447 2.41E-17 1.74E-16
shNTC NTC 0.142722 14.67407 16.20187 5.69E-05 0.000171
shPTCRA#1 PTCRA 1.162686 12.44823 97.1251 6.51E-23 1.17E-21
shPTCRA#2 PTCRA -0.09302 14.33642 5.450512 0.019563 0.033536
shPTCRA#3 PTCRA 0.045001 14.68605 1.3185 0.250862 0.301034
shPTEN#1 PTEN 0.192277 15.38286 23.49149 1.25E-06 4.52E-06
shPTEN#2 PTEN 0.360431 15.34098 60.10506 8.99E-15 4.62E-14
shPTEN#3 PTEN 0.324605 15.09946 68.71281 1.14E-16 6.83E-16
shRPL9#1 RPL9 -1.21206 13.30871 93.49248 4.08E-22 4.89E-21
shRPL9#2 RPL9 -0.54714 14.65503 57.88878 2.77E-14 1.25E-13
shRPS29#1 RPS29 -0.1659 15.04966 12.06883 0.000513 0.001231
shRPS29#2 RPS29 1.390155 11.19096 116.9687 2.92E-27 1.05E-25
shRUNX1/ETORUNX1/ETO -0.05371 15.45031 2.394155 0.12179 0.162386
shSESN2 SESN2 0.05198 14.32832 0.702013 0.402108 0.438663
shTRPM7#1 TRPM7 -0.07996 15.19215 4.631726 0.031386 0.04911
shTRPM7#2 TRPM7 -0.01993 14.77305 0.300749 0.583413 0.583413
shZAP70#1 ZAP70 -0.14588 14.20112 12.15537 0.000489 0.001231
shZAP70#2 ZAP70 0.060226 15.03983 1.719252 0.189789 0.235601
shZAP70#3 ZAP70 0.307299 14.0987 40.39811 2.07E-10 8.29E-10
Slope = regression slope
LogCPM = log counts per million
LR = linear regression
Pvalue = calculated probability
FDR = false discovery rate
Supplementary Table 2. Change in shRNA count over time in HPB-ALL.
shRNA gene slope logCPM LR PValue FDR
shCD19#1 CD19 0.076676 14.63632 1.36868 0.242039 0.484078
shCD19#2 CD19 0.304433 14.16582 2.526258 0.111965 0.310058
shCD3e#1 CD3e 0.053084 14.7422 0.320321 0.571415 0.734676
shCD3e#2 CD3e 0.000262 14.94729 1.06E-05 0.997398 0.997398
shCD3e#3 CD3e 0.097748 14.92095 1.407473 0.235476 0.484078
shDDB2 DDB2 -0.01769 15.59403 0.083688 0.77236 0.896935
shERGIC3 ERGIC3 0.1602 14.77733 5.377864 0.020394 0.183544
shFLG FLG 0.003909 15.84047 0.005994 0.938291 0.965099
shFYN#1 FYN 0.007742 14.81366 0.018907 0.890633 0.948472
shFYN#2 FYN -0.11644 15.07516 1.8726 0.171178 0.38515
shFYN#3 FYN 0.104816 14.56482 2.537008 0.111205 0.310058
shKLHL7 KLHL7 0.130125 14.88374 4.360828 0.036774 0.231921
shLAT#1 LAT -0.05618 14.38549 0.709075 0.399751 0.654138
shLAT#2 LAT 0.420649 13.73192 2.350098 0.125275 0.316841
shLAT#3 LAT -0.0557 14.45989 0.731144 0.392513 0.654138
shLCK#1 LCK -0.13122 14.76446 4.085409 0.043255 0.231921
shLCK#2 LCK -0.16797 15.34151 3.129431 0.076891 0.275791
shLCK#3 LCK -0.49393 14.57817 37.60301 8.67E-10 3.12E-08
shNTC NTC 0.214847 14.77209 2.980575 0.084269 0.275791
shPTCRA#1 PTCRA 0.267687 12.7532 0.208158 0.648215 0.777858
shPTCRA#2 PTCRA -0.19116 14.18089 7.283953 0.006957 0.083488
shPTCRA#3 PTCRA -0.03215 14.61697 0.239374 0.624659 0.775439
shPTEN#1 PTEN 0.030015 15.12332 0.320785 0.571136 0.734676
shPTEN#2 PTEN 0.109527 14.80355 4.015054 0.045096 0.231921
shPTEN#3 PTEN 0.037494 14.68379 0.428577 0.512688 0.734676
shRPL9#1 RPL9 -0.01118 14.45504 0.023847 0.877274 0.948472
shRPL9#2 RPL9 0.007072 15.13202 0.01716 0.895779 0.948472
shRPS29#1 RPS29 -0.32417 14.50428 13.0007 0.000311 0.005605
shRPS29#2 RPS29 0.455703 11.59586 0.554487 0.45649 0.714506
shRUNX1/ETORUNX1/ETO -0.04558 15.46496 0.32547 0.568339 0.734676
shSESN2 SESN2 0.119695 14.52444 2.268625 0.132017 0.316841
shTRPM7#1 TRPM7 -0.04328 15.18369 0.357437 0.549933 0.734676
shTRPM7#2 TRPM7 0.073465 14.78222 0.850954 0.356283 0.641309
shZAP70#1 ZAP70 -0.06882 14.24169 1.04734 0.30612 0.580018
shZAP70#2 ZAP70 0.136615 15.01813 3.505103 0.06118 0.27531
shZAP70#3 ZAP70 0.347658 14.31406 3.121749 0.077254 0.275791
Slope = regression slope
LogCPM = log counts per million
LR = linear regression
Pvalue = calculated probability
FDR = false discovery rate
Supplementary Table 2. Change in shRNA count over time in MOLT4.
shRNA gene slope logCPM LR PValue FDR
shCD19#1 CD19 -0.04584 14.65114 0.636513 0.424976 0.546398
shCD19#2 CD19 0.12862 14.4973 5.898472 0.015154 0.030308
shCD3e#1 CD3e -0.24225 14.39331 19.64187 9.34E-06 3.36E-05
shCD3e#2 CD3e -0.14202 14.55194 6.734616 0.009456 0.020024
shCD3e#3 CD3e -0.09928 14.71464 3.841146 0.050009 0.090017
shDDB2 DDB2 0.08035 15.58186 2.732132 0.098348 0.153936
shERGIC3 ERGIC3 0.065503 14.82244 1.627733 0.202017 0.28986
shFLG FLG 0.018123 15.83752 0.129273 0.719188 0.809086
shFYN#1 FYN -0.07978 14.72385 2.471572 0.115922 0.173883
shFYN#2 FYN 0.027577 15.02277 0.293038 0.58828 0.705936
shFYN#3 FYN 0.08937 14.62285 2.836867 0.092124 0.150748
shKLHL7 KLHL7 0.162163 15.11518 8.211222 0.004163 0.009367
shLAT#1 LAT -0.01131 14.34605 0.043935 0.833974 0.857802
shLAT#2 LAT 0.273 14.31746 14.00058 0.000183 0.000598
shLAT#3 LAT -0.04232 14.63143 0.364078 0.54625 0.678104
shLCK#1 LCK -0.34628 14.26935 25.45437 4.53E-07 2.04E-06
shLCK#2 LCK -0.06171 15.14572 1.575962 0.209343 0.28986
shLCK#3 LCK -0.61735 13.94143 52.16641 5.10E-13 6.12E-12
shNTC NTC 0.062558 15.05358 1.325919 0.249533 0.33271
shPTCRA#1 PTCRA -0.07778 12.83142 0.260297 0.609916 0.70829
shPTCRA#2 PTCRA -0.54271 13.57462 46.17613 1.08E-11 9.73E-11
shPTCRA#3 PTCRA -0.35518 14.13973 12.15597 0.000489 0.001258
shPTEN#1 PTEN 0.289544 15.57128 20.91663 4.80E-06 1.92E-05
shPTEN#2 PTEN 0.282258 15.35395 35.02909 3.25E-09 2.34E-08
shPTEN#3 PTEN 0.424263 15.38662 32.73342 1.06E-08 6.34E-08
shRPL9#1 RPL9 -0.55786 13.85047 67.01331 2.70E-16 4.85E-15
shRPL9#2 RPL9 -0.18126 14.89238 12.83435 0.00034 0.001021
shRPS29#1 RPS29 -0.53123 14.29437 72.14488 2.00E-17 7.20E-16
shRPS29#2 RPS29 0.628086 12.66522 8.708742 0.003167 0.007601
shRUNX1/ETORUNX1/ETO 0.012942 15.29902 0.067097 0.795612 0.842413
shSESN2 SESN2 0.129881 14.83796 5.430274 0.019791 0.037498
shTRPM7#1 TRPM7 -0.00974 15.0676 0.025845 0.87228 0.87228
shTRPM7#2 TRPM7 -0.19066 14.65694 12.51527 0.000404 0.001118
shZAP70#1 ZAP70 -0.37416 13.77377 31.02042 2.55E-08 1.31E-07
shZAP70#2 ZAP70 0.02048 15.15053 0.069517 0.792042 0.842413
shZAP70#3 ZAP70 0.121387 14.66767 3.03661 0.081406 0.139553
Slope = regression slope
LogCPM = log counts per million
LR = linear regression
Pvalue = calculated probability
FDR = false discovery rate
Supplementary Table 2. Change in shRNA count over time in SUPT1.
Supplementary Table 3. Change in shRNA count over time in PDX L963 in vivo BM.
shRNA logFC logCPM LR PValue FDR
shLCK#3 -8.57718 12.38082 26.24361 3.01E-07 1.08E-05
shRPL9#1 -6.49117 11.56515 9.817988 0.001728 0.031106
shCD19#2 -3.25763 12.52308 6.059984 0.013828 0.160969
shERGIC3 4.058343 16.74306 5.607333 0.017885 0.160969
shPTEN#1 -2.94281 16.29354 3.816812 0.050741 0.365333
shPTEN#3 -2.59947 12.77494 3.110715 0.077779 0.390707
shLAT#3 -2.39486 13.02144 3.075171 0.079496 0.390707
shLAT#2 -1.92967 12.92357 2.9323 0.086824 0.390707
shPTCRA#2 1.95272 16.3038 1.774488 0.182828 0.731311
shKLHL7 -1.47015 14.4175 1.514979 0.218381 0.762553
shFYN#1 -1.3497 13.22957 1.422439 0.233002 0.762553
shDDB2 1.461431 16.93928 1.028954 0.310405 0.906671
shCD3E#2 -1.28722 13.91845 0.959119 0.327409 0.906671
shCD3E#3 -1.04132 14.28719 0.636985 0.424805 0.922599
shZAP70#3 1.02018 14.20344 0.618771 0.431504 0.922599
shSESN2 -0.82483 14.09281 0.494419 0.481963 0.922599
shLCK#2 0.795998 15.19829 0.363831 0.546386 0.922599
shRUNX1/ETO -0.78189 13.95386 0.338049 5.61E-01 9.23E-01
shZAP70#2 -0.53391 14.9653 0.236764 0.626553 0.922599
shTRPM7#1 -0.6809 16.76503 0.20726 0.648923 0.922599
shNTC 0.408758 14.50807 0.155089 0.693718 0.922599
shLCK#1 0.737421 14.11903 0.153269 0.695431 0.922599
shCD19#1 0.678317 15.03059 0.145387 0.702983 0.922599
shZAP70#1 -0.68116 13.5309 0.126603 0.721981 0.922599
shFYN#3 0.510772 14.69092 0.11697 0.732345 0.922599
shRPS29#1 -0.44438 14.52556 0.095859 0.756857 0.922599
shRPL9#2 0.47237 14.19795 0.091172 0.762693 0.922599
shFLG -0.37716 15.06153 0.081228 0.775641 0.922599
shFYN#2 -0.41495 14.25891 0.079526 0.777941 0.922599
shLAT#1 0.35956 15.05768 0.050328 0.822494 0.922599
shPTCRA#3 -0.26426 13.87086 0.047526 0.827426 0.922599
shTRPM7#2 -0.26199 14.70756 0.03781 0.845825 0.922599
shPTEN#2 -0.24905 14.2727 0.027004 0.869473 0.922599
shPTCRA#1 -0.2584 12.41615 0.026229 0.871343 0.922599
shCD3E#1 0.050404 15.02011 0.001907 0.965171 0.965706
shRPS29#2 0.08799 10.95056 0.001849 0.965706 0.965706
LogFC = log fold change
LogCPM = log counts per million
LR = linear regression
Pvalue = calculated probability
FDR = false discovery rate
Supplementary Table 3. Change in shRNA count over time in PDX L963 in vivo spleen.
shRNA logFC logCPM LR PValue FDR
shLCK#3 -8.03321 12.38082 31.3336 2.17E-08 7.82E-07
shRPL9#1 -6.10375 11.56515 10.30905 0.001324 0.023828
shCD19#2 -3.204 12.52308 5.983788 0.014438 0.173256
shFYN#1 -1.84535 13.22957 3.100858 0.078251 0.70426
shPTEN#3 -2.03758 12.77494 2.452733 0.11732 0.844707
shERGIC3 2.276879 16.74306 2.167813 0.140927 0.845559
shPTEN#1 -1.68258 16.29354 1.21885 0.269586 0.97833
shZAP70#1 -1.7052 13.5309 1.21095 0.271144 0.97833
shRUNX1/ETO -1.24494 13.95386 1.073682 0.300115 0.97833
shSESN2 -1.19801 14.09281 0.952131 0.329178 0.97833
shLAT#3 -1.22223 13.02144 0.900891 0.342543 0.97833
shPTCRA#2 1.322231 16.3038 0.800911 0.370821 0.97833
shKLHL7 -1.08219 14.4175 0.763621 0.382198 0.97833
shCD3E#2 -1.11341 13.91845 0.727283 0.393765 0.97833
shLAT#1 1.335508 15.05768 0.68568 0.407638 0.97833
shLAT#2 -0.97306 12.92357 0.572829 0.449137 0.983201
shCD19#1 1.115446 15.03059 0.441655 0.506325 0.983201
shCD3E#3 -0.60982 14.28719 0.219188 0.63966 0.983201
shDDB2 0.588038 16.93928 0.207383 0.648827 0.983201
shFYN#3 0.565636 14.69092 0.16716 0.682649 0.983201
shNTC 0.412178 14.50807 0.165008 0.684587 0.983201
shLCK#1 -0.76202 14.11903 0.157834 0.691159 0.983201
shCD3E#1 -0.43304 15.02011 0.143895 0.704439 0.983201
shFYN#2 -0.49307 14.25891 0.119843 0.729204 0.983201
shFLG -0.38268 15.06153 0.093593 0.759658 0.983201
shPTCRA#1 -0.34852 12.41615 0.050705 0.821841 0.983201
shTRPM7#1 0.316594 16.76503 0.044782 0.832406 0.983201
shPTCRA#3 -0.23218 13.87086 0.042135 0.837362 0.983201
shZAP70#2 0.20482 14.9653 0.0318 0.858466 0.983201
shTRPM7#2 -0.15276 14.70756 0.012512 0.910937 0.983201
shPTEN#2 0.157617 14.2727 0.011548 0.914423 0.983201
shLCK#2 0.12677 15.19829 0.010496 0.918399 0.983201
shRPL9#2 -0.12975 14.19795 0.008017 0.928657 0.983201
shZAP70#3 0.053671 14.20344 0.001976 0.964547 0.983201
shRPS29#1 0.037446 14.52556 0.000707 0.978787 0.983201
shRPS29#2 -0.04447 10.95056 0.000443 0.983201 0.983201
LogFC = log fold change
LogCPM = log counts per million
LR = linear regression
Pvalue = calculated probability
FDR = false discovery rate
Supplementary Table 3. Change in shRNA count over time in PDX LK203 ex vivo.
shRNA logFC logCPM LR PValue FDR
shRPL9#2 -2.34442 14.34755 57.47394 3.42E-14 1.23E-12
shRPS29#1 -3.28914 13.91702 18.12502 2.07E-05 0.0003
shSESN2 1.058582 14.68708 17.23154 3.31E-05 0.0003
shERGIC3 1.769788 15.65966 17.22071 3.33E-05 0.0003
shPTEN#3 0.97378 15.07812 15.42601 8.58E-05 0.000618
shLCK#1 -0.77115 14.55244 10.42664 0.001242 0.007453
shLAT#1 -0.79255 14.38541 10.03618 1.53E-03 0.007894
shZAP70#3 0.913031 14.12767 8.893602 0.002862 0.012878
shLCK#2 -0.67921 15.12368 7.527476 0.006076 0.022739
shLAT#3 -0.81492 14.37636 7.457751 0.006316 0.022739
shRPL9#1 -1.72479 13.97955 5.985659 0.014423 0.047201
shLCK#3 -0.65503 15.0903 5.812054 0.015917 0.04775
shPTEN#2 0.577326 15.27768 4.590465 0.03215 0.086249
shTRPM7#2 -0.69319 14.87496 4.517927 0.033541 0.086249
shCD19#2 0.563898 14.21015 3.744642 0.052977 0.122818
shPTEN#1 0.513298 14.97789 3.6947 0.054586 0.122818
shTRPM7#1 0.619672 15.45041 3.558532 0.05924 0.12545
shPTCRA#3 -0.53497 14.5679 3.154093 0.075737 0.151474
shNTC 0.43134 14.77022 2.861392 0.090729 0.171907
shFYN#1 -0.45909 14.66029 2.5511 0.110218 0.198392
shPTCRA#2 -0.94997 14.01477 2.396064 0.121641 0.208527
shCD3E#3 0.350878 14.81547 2.265706 0.132266 0.216245
shFYN#2 -0.36781 15.08274 2.198372 0.138157 0.216245
shCD3E#2 0.363319 15.12521 1.809009 0.178627 0.267941
shPTCRA#1 0.764157 13.1688 1.504773 2.20E-01 0.316711
shCD3E#1 0.284976 14.5903 1.312212 0.251995 0.343891
shRPS29#2 0.792341 10.99167 1.273523 2.59E-01 3.44E-01
shKLHL7 0.278821 14.20479 1.229674 2.67E-01 0.343891
shRUNX1/ETO -0.26394 15.47563 1.101449 0.293948 0.364901
shDDB2 -0.24191 15.4647 0.99148 0.319381 0.383257
shZAP70#1 -0.2403 14.2102 0.766361 3.81E-01 0.442853
shCD19#1 0.151835 14.9887 0.447914 0.503327 0.566243
shFYN#3 0.134089 14.51175 0.32771 0.567011 0.618557
shLAT#2 0.173499 13.50733 0.187032 0.665398 0.704539
shFLG 0.026086 15.75399 0.011679 0.913942 0.9148
shZAP70#2 -0.02632 15.0016 0.011446 0.9148 0.9148
LogFC = log fold change
LogCPM = log counts per million
LR = linear regression
Pvalue = calculated probability
FDR = false discovery rate
Name Sequences Primer Seq Read
1 CAAGCAGAAGACGGCATACGAGATCGTGATATTTATACCATTTTAATTCAGCTTTGT CGTGAT ATCACG
2 CAAGCAGAAGACGGCATACGAGATACATCGATTTATACCATTTTAATTCAGCTTTGT ACATCG CGATGT
3 CAAGCAGAAGACGGCATACGAGATGCCTAAATTTATACCATTTTAATTCAGCTTTGT GCCTAA TTAGGC
4 CAAGCAGAAGACGGCATACGAGATTGGTCAATTTATACCATTTTAATTCAGCTTTGT TGGTCA TGACCA
5 CAAGCAGAAGACGGCATACGAGATCACTGTATTTATACCATTTTAATTCAGCTTTGT CACTGT ACAGTG
6 CAAGCAGAAGACGGCATACGAGATATTGGCATTTATACCATTTTAATTCAGCTTTGT ATTGGC GCCAAT
7 CAAGCAGAAGACGGCATACGAGATGATCTGATTTATACCATTTTAATTCAGCTTTGT GATCTG CAGATC
8 CAAGCAGAAGACGGCATACGAGATTCAAGTATTTATACCATTTTAATTCAGCTTTGT TCAAGT ACTTGA
9 CAAGCAGAAGACGGCATACGAGATCTGATCATTTATACCATTTTAATTCAGCTTTGT CTGATC GATCAG
10 CAAGCAGAAGACGGCATACGAGATAAGCTAATTTATACCATTTTAATTCAGCTTTGT AAGCTA TAGCTT
11 CAAGCAGAAGACGGCATACGAGATGTAGCCATTTATACCATTTTAATTCAGCTTTGT GTAGCC GGCTAC
12 CAAGCAGAAGACGGCATACGAGATTACAAGATTTATACCATTTTAATTCAGCTTTGT TACAAG CTTGTA
13 CAAGCAGAAGACGGCATACGAGATTTGACTATTTATACCATTTTAATTCAGCTTTGT TTGACT AGTCAA
14 CAAGCAGAAGACGGCATACGAGATGGAACTATTTATACCATTTTAATTCAGCTTTGT GGAACT AGTTCC
15 CAAGCAGAAGACGGCATACGAGATTGACATATTTATACCATTTTAATTCAGCTTTGT TGACAT ATGTCA
16 CAAGCAGAAGACGGCATACGAGATGGACGGATTTATACCATTTTAATTCAGCTTTGT GGACGG CCGTCC
17 CAAGCAGAAGACGGCATACGAGATCTCTACATTTATACCATTTTAATTCAGCTTTGT CTCTAC GTAGAG
18 CAAGCAGAAGACGGCATACGAGATGCGGACATTTATACCATTTTAATTCAGCTTTGT GCGGAC GTCCGC
19 CAAGCAGAAGACGGCATACGAGATTTTCACATTTATACCATTTTAATTCAGCTTTGT TTTCAC GTGAAA
20 CAAGCAGAAGACGGCATACGAGATGTGGCCATTTATACCATTTTAATTCAGCTTTGT GTGGCC GTGGCC
21 CAAGCAGAAGACGGCATACGAGATCGAAACATTTATACCATTTTAATTCAGCTTTGT CGAAAC GTTTCG
22 CAAGCAGAAGACGGCATACGAGATCGTACGATTTATACCATTTTAATTCAGCTTTGT CGTACG CGTACG
23 CAAGCAGAAGACGGCATACGAGATCCACTCATTTATACCATTTTAATTCAGCTTTGT CCACTC GAGTGG
24 CAAGCAGAAGACGGCATACGAGATGCTACCATTTATACCATTTTAATTCAGCTTTGT GCTACC GGTAGC
25 CAAGCAGAAGACGGCATACGAGATATCAGTATTTATACCATTTTAATTCAGCTTTGT ATCAGT ACTGAT
26 CAAGCAGAAGACGGCATACGAGATGCTCATATTTATACCATTTTAATTCAGCTTTGT GCTCAT ATGAGC
27 CAAGCAGAAGACGGCATACGAGATAGGAATATTTATACCATTTTAATTCAGCTTTGT AGGAAT ATTCCT
28 CAAGCAGAAGACGGCATACGAGATCTTTTGATTTATACCATTTTAATTCAGCTTTGT CTTTTG CAAAAG
29 CAAGCAGAAGACGGCATACGAGATTAGTTGATTTATACCATTTTAATTCAGCTTTGT TAGTTG CAACTA
30 CAAGCAGAAGACGGCATACGAGATCCGGTGATTTATACCATTTTAATTCAGCTTTGT CCGGTG CACCGG
31 CAAGCAGAAGACGGCATACGAGATATCGTGATTTATACCATTTTAATTCAGCTTTGT ATCGTG CACGAT
Supplementary Table 4. Barcode sequences used in library preparation 
32 CAAGCAGAAGACGGCATACGAGATTGAGTGATTTATACCATTTTAATTCAGCTTTGT TGAGTG CACTCA
33 CAAGCAGAAGACGGCATACGAGATGCGGACATTTATACCATTTTAATTCAGCTTTGT GCGGAC GCGGAC
34 CAAGCAGAAGACGGCATACGAGATGCCATGATTTATACCATTTTAATTCAGCTTTGT GCCATG CATGGC
35 CAAGCAGAAGACGGCATACGAGATAAAATGATTTATACCATTTTAATTCAGCTTTGT AAAATG CATTTT
36 CAAGCAGAAGACGGCATACGAGATTGTTGGATTTATACCATTTTAATTCAGCTTTGT TGTTGG CCAACA
37 CAAGCAGAAGACGGCATACGAGATATTCCGATTTATACCATTTTAATTCAGCTTTGT ATTCCG CGGAAT
38 CAAGCAGAAGACGGCATACGAGATAGCTAGATTTATACCATTTTAATTCAGCTTTGT AGCTAG CTAGCT
39 CAAGCAGAAGACGGCATACGAGATGTATAGATTTATACCATTTTAATTCAGCTTTGT GTATAG CTATAC
40 CAAGCAGAAGACGGCATACGAGATTCTGAGATTTATACCATTTTAATTCAGCTTTGT TCTGAG CTCAGA
41 CAAGCAGAAGACGGCATACGAGATGTCGTCATTTATACCATTTTAATTCAGCTTTGT GTCGTC GACGAC
42 CAAGCAGAAGACGGCATACGAGATCGATTAATTTATACCATTTTAATTCAGCTTTGT CGATTA TAATCG
43 CAAGCAGAAGACGGCATACGAGATGCTGTAATTTATACCATTTTAATTCAGCTTTGT GCTGTA TACAGC
44 CAAGCAGAAGACGGCATACGAGATATTATAATTTATACCATTTTAATTCAGCTTTGT ATTATA TATAAT
45 CAAGCAGAAGACGGCATACGAGATGAATGAATTTATACCATTTTAATTCAGCTTTGT GAATGA TCATTC
46 CAAGCAGAAGACGGCATACGAGATTCGGGAATTTATACCATTTTAATTCAGCTTTGT TCGGGA TCCCGA
47 CAAGCAGAAGACGGCATACGAGATCTTCGAATTTATACCATTTTAATTCAGCTTTGT CTTCGA TCGAAG
48 CAAGCAGAAGACGGCATACGAGATTGCCGAATTTATACCATTTTAATTCAGCTTTGT TGCCGA TCGGCA
49 CAAGCAGAAGACGGCATACGAGATTAGCGCATTTATACCATTTTAATTCAGCTTTGT TAGCGC GCGCTA
50 CAAGCAGAAGACGGCATACGAGATGTGTTTATTTATACCATTTTAATTCAGCTTTGT GTGTTT AAACAC
51 CAAGCAGAAGACGGCATACGAGATCCTTCAATTTATACCATTTTAATTCAGCTTTGT CCTTCA TGAAGG
52 CAAGCAGAAGACGGCATACGAGATTATGTTATTTATACCATTTTAATTCAGCTTTGT TATGTT AACATA
53 CAAGCAGAAGACGGCATACGAGATGACGCGATTTATACCATTTTAATTCAGCTTTGT GACGCG CGCGTC
54 CAAGCAGAAGACGGCATACGAGATTGTATCATTTATACCATTTTAATTCAGCTTTGT TGTATC GATACA
55 CAAGCAGAAGACGGCATACGAGATCACACCATTTATACCATTTTAATTCAGCTTTGT CACACC GGTGTG
56 CAAGCAGAAGACGGCATACGAGATTTCTTAATTTATACCATTTTAATTCAGCTTTGT TTCTTA TAAGAA
57 CAAGCAGAAGACGGCATACGAGATCTCGCTATTTATACCATTTTAATTCAGCTTTGT CTCGCT AGCGAG
58 CAAGCAGAAGACGGCATACGAGATTAACCGATTTATACCATTTTAATTCAGCTTTGT TAACCG CGGTTA
59 CAAGCAGAAGACGGCATACGAGATAAAGCTATTTATACCATTTTAATTCAGCTTTGT AAAGCT AGCTTT
60 CAAGCAGAAGACGGCATACGAGATAGACCAATTTATACCATTTTAATTCAGCTTTGT AGACCA TGGTCT
61 CAAGCAGAAGACGGCATACGAGATGGGATAATTTATACCATTTTAATTCAGCTTTGT GGGATA TATCCC
62 CAAGCAGAAGACGGCATACGAGATACGACAATTTATACCATTTTAATTCAGCTTTGT ACGACA TGTCGT
63 CAAGCAGAAGACGGCATACGAGATGTGGGGATTTATACCATTTTAATTCAGCTTTGT GTGGGG CCCCAC
64 CAAGCAGAAGACGGCATACGAGATTCGTATATTTATACCATTTTAATTCAGCTTTGT TCGTAT ATACGA
65 CAAGCAGAAGACGGCATACGAGATCAAGGGATTTATACCATTTTAATTCAGCTTTGT CAAGGG CCCTTG
66 CAAGCAGAAGACGGCATACGAGATGCCGGTATTTATACCATTTTAATTCAGCTTTGT GCCGGT ACCGGC
67 CAAGCAGAAGACGGCATACGAGATCAGTAAATTTATACCATTTTAATTCAGCTTTGT CAGTAA TTACTG
68 CAAGCAGAAGACGGCATACGAGATAGTTCCATTTATACCATTTTAATTCAGCTTTGT AGTTCC GGAACT
69 CAAGCAGAAGACGGCATACGAGATAATAACATTTATACCATTTTAATTCAGCTTTGT AATAAC GTTATT
70 CAAGCAGAAGACGGCATACGAGATACTTTTATTTATACCATTTTAATTCAGCTTTGT ACTTTT AAAAGT
71 CAAGCAGAAGACGGCATACGAGATTCCCTTATTTATACCATTTTAATTCAGCTTTGT TCCCTT AAGGGA
72 CAAGCAGAAGACGGCATACGAGATATACTTATTTATACCATTTTAATTCAGCTTTGT ATACTT AAGTAT
73 CAAGCAGAAGACGGCATACGAGATAGATGTATTTATACCATTTTAATTCAGCTTTGT AGATGT ACATCT
74 CAAGCAGAAGACGGCATACGAGATAATCGTATTTATACCATTTTAATTCAGCTTTGT AATCGT ACGATT
75 CAAGCAGAAGACGGCATACGAGATCGGCGTATTTATACCATTTTAATTCAGCTTTGT CGGCGT ACGCCG
76 CAAGCAGAAGACGGCATACGAGATGAGAGTATTTATACCATTTTAATTCAGCTTTGT GAGAGT ACTCTC
77 CAAGCAGAAGACGGCATACGAGATGATTCTATTTATACCATTTTAATTCAGCTTTGT GATTCT AGAATC
78 CAAGCAGAAGACGGCATACGAGATCCCAATATTTATACCATTTTAATTCAGCTTTGT CCCAAT ATTGGG
79 CAAGCAGAAGACGGCATACGAGATACGCGGATTTATACCATTTTAATTCAGCTTTGT ACGCGG CCGCGT
80 CAAGCAGAAGACGGCATACGAGATAGGGCGATTTATACCATTTTAATTCAGCTTTGT AGGGCG CGCCCT
81 CAAGCAGAAGACGGCATACGAGATCTGCAGATTTATACCATTTTAATTCAGCTTTGT CTGCAG CTGCAG
82 CAAGCAGAAGACGGCATACGAGATAACTTCATTTATACCATTTTAATTCAGCTTTGT AACTTC GAAGTT
83 CAAGCAGAAGACGGCATACGAGATGGGTGCATTTATACCATTTTAATTCAGCTTTGT GGGTGC GCACCC
84 CAAGCAGAAGACGGCATACGAGATTCCTGCATTTATACCATTTTAATTCAGCTTTGT TCCTGC GCAGGA
85 CAAGCAGAAGACGGCATACGAGATCGCGGCATTTATACCATTTTAATTCAGCTTTGT CGCGGC GCCGCG
86 CAAGCAGAAGACGGCATACGAGATACCGCCATTTATACCATTTTAATTCAGCTTTGT ACCGCC GGCGGT
87 CAAGCAGAAGACGGCATACGAGATTAATACATTTATACCATTTTAATTCAGCTTTGT TAATAC GTATTA
88 CAAGCAGAAGACGGCATACGAGATCACGTAATTTATACCATTTTAATTCAGCTTTGT CACGTA TACGTG
89 CAAGCAGAAGACGGCATACGAGATATGTGAATTTATACCATTTTAATTCAGCTTTGT ATGTGA TCACAT
Name Sequences
NGS-F3 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCATGGACGAGCTGTACAAGT
Forward amplification primer
Gene Seq
LCK-F CACGCTGCTCATCCGAAATG
LCK-R ACCAGGTTGTCTTGCAGTGG
PTCRA-F TGGATGCCTTCACCTATGGC
PTCRA-R AAGCCTCTCCTGACAGATGC
ZAP70-F GAACTTTGTGCACCGTGACC
ZAP70-R CTGAGCGGGCAGTGTAGTAG
FYN-F TACCCAGGCATGAACAACCG
FYN-R GTTGGTACTGGGGCTCTGTC
GILZ-F CATGGAGGTGGCGGTCTA
GILZ-R TTACACCGCAGAACCACCAG
Supplementary Table 5. Primer sequences.
UPN Gender Age (years) Time-point White cell count (10E-9/L) Cytogenetics Subgroup Molecular
L809 Male 16 diagnosis 319 46,XY,del(6)(q13q23). Extra RUNX1 signal [11%] TAL1 nk nk = not known
L903 Female 4 diagnosis nk 46,XX. STIL-TAL1 TAL1 nk
L907 Male 12 diagnosis nk 46,XY TAL2 nk
L963 Male 4 diagnosis 104 46,XY,r(5)(p14q23),del(7)(q22) nk nk
L970 Male 11 diagnosis 316 t(5;14)(q35;q32) BCL11B-TLX3 TLX3 nk
LK080 Male 1 relapse 19 46,XY nk nk
LK203 Female 4 diagnosis 760 46,XX TCRA-LMO2? Deletion CDKN2A, PTEN
LK287 Male 15 diagnosis 272 46,XY,del(6)(q14~16q23). STIL-TAL1. FIP1L1-PDGFRA. TAL1 nk
LK290 Male 15 diagnosis 75 46,XY. t(11;19)(q23;p13.3) KMT2A-MLLT1 KMT2A nk
Cell line Gender Age (years) Disease ATCC / DSMZ Cytogenetics TCR status Mutation Deletion
SUPT1  Male 8 T-LBL CRL 1942 t(7;9)(q34;q34.3) pTCR+ CDKN2B
Relapse TRB-NOTCH1/TAN1 TCRαβ- CDKN2A
Inv(14)(q11q32)
TRAD-IGH
CUTLL1  Male 14 T-NHL t(7;9)(q34;q34) TCRαβ+ TP53
Relapse TRB-NOTCH 
HPB-ALL Male 14 T-ALL ACC 483 t(5;14)(q35;q32.2) TCRαβ+ IFNB
Diagnosis HOX11L2/TLX3-BCL11B CDKN2B
pseudodiploid with 8% polyploidy CDKN2A
HSB-2 Male 11 T-ALL ACC 435 t(1;7)(p34;q34) TCRαβ- LCKV28L
LCK-TRB LCKA353V
submicroscopic del(1)(p32) LCKP447L
STIL-TAL1(SIL-SCL) LCK p.232_233insQKP
pseudodiploid with 4% polyploidy
MOLT4 Male 19 T-ALL CRL 1582 hypertetraploid TCRαβ- NRAS CDKN2A
Relapse ACC 362 pTCR+ TP53
PTEN
Jurkat  Male 14 T-ALL TIB 152 pseudodiploid TCRαβ+ TP53 p.T125T IFNA
Relapse PTEN p.R234fs, p.L247fs CDKN2B CDKN2A
LCK p.L251fs
MOLT16 Female 5  T-ALL ACC 29 t(8;14)(q24;;q11) TCRαβ+ TP53 CDKN2B CDKN2A
Relapse MYC-TRAD, PTEN
submicroscopic del(1)(p32) SIL-TAL1/SCL fusion
near-diploid
KOPT-K1 Male 6 T-NHL t(11;14)(p13;q11) LMO2/TTG2-TRD TCRαβ- CDKN2A
DU.528 Male  16  T-ALL 40625 t(1;14)(p32;q11) TCRαβ-
Diagnosis TAL1/SCL-TRD 
ALLSIL Male 17  T-ALL ACC 511 t(10;14)(q24;q11) TLX1/HOX11-TRAD TCRαβ- IFNA
Relapse NUP214-ABL1 IFNB
hypertetraploid CDKN2B
CDKN2A
RB1
CCRF-CEM Female 3 T-ALL CCL 119 submicroscopic del(1)(p32) TCRαβ+ TP53 IFNA
Relapse ACC 240 SIL-TAL1/SCL KRAS IFNB
t(5;14)(q35.1;q32.2) CDKN2A
NKX2-5-BCL11B 
near-tetraploid
Supplementary Table 6. Patient and cell line characteristics.
